ClinicalTrials.gg
CompletedNCT06238817TRuE-AD4Updated Oct 15, 2026Results posted

A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis

A Phase 3 interventional study of Ruxolitinib Cream and Vehicle Cream in Atopic Dermatitis, sponsored by Incyte Corporation. Completed at 94 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Incyte Corporation · Phase 3, Interventional, and Treatment

Updated Oct 15, 2026Posted results revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
241
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing ruxolitinib in Dermatitis, Atopic — 2 open to participants now, 3 under way, 1 of them phase 3. ruxolitinib · Dermatitis, Atopic.

Enrollment
5th of 15
241 · median 77
Started
2024
the only one that year
Phase 3
6 of 15
none open now
Registered
12th of 15
by date
Lead sponsor
13 of 15
Incyte Corporation

Among the 15 studies testing ruxolitinib in Dermatitis, Atopic, this one is the 5th largest by enrollment, is the only one that started in 2024, is one of 6 in phase 3, and was the 12th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

2 of the 15 studies testing ruxolitinib in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About ruxolitinib

ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing ruxolitinib in Dermatitis, Atopic, or all of them as a file.
02

Study summary

This study is being conducted to establish the efficacy of ruxolitinib cream in participants with moderate AD who had an inadequate response to, or are intolerant to, or contraindicated to topical corticosteroid (TCS)s and topical calcineurin inhibitor (TCI)s.

03

Conditions studied

  • Atopic Dermatitis

Keywords

  • Atopic dermatitis
  • pruritus
  • eczema
  • topical therapy
  • JAK inhibitor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged ≥ 18 years at screening (Note: Legal adult age for Korea is ≥ 19 years).
  • Diagnosis of AD as defined by the Hanifin and Rajka (1980) criteria.
  • AD duration of at least 2 years.
  • IGA score of 3 at screening and Day 1.
  • EASI score > 7 at screening and Day 1.
  • Itch NRS score ≥ 4 at Day 1, defined as the average of the 7 days directly before Day 1, with Itch NRS values available for at least 4 of the 7 days.
  • %BSA (excluding the scalp) with AD involvement of at least 10% and up to 20% at screening and Day 1.
  • DLQI score > 10 at screening and Day 1.
  • Documented recent history (within 12 months before the screening visit) of inadequate response, intolerance, or to TCSs and TCIs.
  • Agree to discontinue all agents used to treat AD from screening through the final follow up visit, except as outlined in the protocol.
  • Willingness to avoid pregnancy or fathering children based on the criteria as outlined in the protocol.

Exclusion criteria

Exclusion Criteria:

  • Unstable course of AD (spontaneously improving or rapidly deteriorating) as determined by the investigator in the 4 weeks prior to Day 1.
  • Concurrent conditions and history of other diseases as follows:

    • (eg, lymphoma, acquired immunodeficiency syndrome, Wiskott-Aldrich syndrome).
    • Chronic or acute infection requiring treatment with systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 2 weeks before Day 1.
    • Active acute bacterial, fungal, or viral skin infection (eg, herpes simplex, herpes zoster, chickenpox) within 1 week before Day 1.
    • Any other concomitant skin disorder (eg, generalized erythroderma, such as Netherton syndrome), pigmentation, or extensive scarring that, in the opinion of the investigator, may interfere with the evaluation of AD lesions or compromise participant safety.
    • Presence of AD lesions only on the hands or feet without prior history of involvement of other classic areas of involvement such as the face or the flexural folds.
    • Other types of eczema within the 6 months prior to screening. Note: Seborrheic dermatitis on the scalp is allowed, as the scalp will not be treated with study cream.
    • Current or history of or C virus infection.
  • Any serious illness or medical, physical, or psychiatric condition(s) that, in the investigator's opinion, would interfere with full participation in the study, including administration of study cream and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.
  • Any of the following clinical laboratory test results at screening:

    • \< 10 g/dL.
    • Liver function tests:

      • or ALT ≥ 2 × .
      • Alkaline phosphatase > 1.5 × ULN.
      • > 1.5 × ULN (isolated bilirubin > 1.5 × ULN is acceptable if bilirubin is fractionated and direct bilirubin \< 35%) with the exception of Gilbert's disease.
    • Estimated \< 30 mL/min/1.73 m2 (using the Chronic Kidney Disease Epidemiology Collaboration equation).
    • Positive serology test results for antibody.
    • Any other laboratory result that, in the opinion of the investigator, poses a significant risk to the participant.
  • Use of any of the following treatments within the indicated before Day 1:

    • 5 half-lives or 12 weeks, whichever is longer: biologic agents. For biologic agents with washout periods longer than 12 weeks (eg, rituximab), consult the medical monitor.
    • 4 weeks: systemic or adrenocorticotropic hormone analogs, cyclosporine, methotrexate, azathioprine, or other systemic immunosuppressive (eg, JAK inhibitors) or immunomodulating agents (eg, mycophenolate or tacrolimus).
    • 2 weeks or 5 half-lives, whichever is longer - strong systemic inhibitors.
    • 2 weeks: immunizations with ; sedating antihistamines unless on a long-term stable regimen (nonsedating antihistamines are permitted).

Note: COVID-19 vaccination is allowed.

  • 1 week: use of other topical treatments for AD, other than bland emollients (eg, Aveeno creams, ointments, sprays, soap substitutes), such as antipruritics (eg, doxepin cream), corticosteroids, calcineurin inhibitors, PDE4 inhibitors, coal tar (shampoo), antibiotics, or antibacterial cleansing body wash/soap.

Note: Diluted sodium hypochlorite "bleach" baths are allowed as long as they do not exceed 2 baths per week and their frequency remains the same throughout the study.

  • History of treatment failure with any systemic or topical JAK inhibitor (eg, ruxolitinib, tofacitinib, baricitinib, abrocitinib, upadacitinib) for AD or any other inflammatory condition.
  • Ultraviolet light therapy or prolonged exposure to natural or artificial sources of UV radiation (eg, sunlight or tanning booth) within 2 weeks prior to the baseline visit and/or intention to have such exposure during the study that is thought by the investigator to potentially impact the participant's AD.
  • Current treatment or treatment within 30 days or 5 half-lives (whichever is longer) before baseline with another medication or current enrollment in another investigational drug protocol.
  • In the opinion of the investigator, are unable or unlikely to comply with the administration schedule, study evaluations, and procedures (eg, eDiary compliance).

Other protocol-defined Inclusion/Exclusion Criteria may apply.

Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
241 participants (actual)

Study arms

  • Experimental
    VC Period: Ruxolitinib 1.5% Cream BID

    Participants received ruxolitinib 1.5% cream, applied topically to the affected areas as a thin film twice daily (BID) from Day 1 to Week 8 during the Vehicle Control (VC) Period. Participants applied cream BID to areas identified at Baseline even if the areas improved.

    Drug: Ruxolitinib Cream

  • Placebo comparator
    VC Period: Vehicle Cream BID

    Participants received vehicle cream, applied topically to the affected areas as a thin film twice daily (BID) from Day 1 to Week 8 during the VC Period. Participants applied cream BID to areas identified at Baseline even if the areas improved.

    Drug: Vehicle Cream

  • Experimental
    VC Extension Period/Escape Arm: Ruxolitinib 1.5% Cream BID

    Participants who applied ruxolitinib 1.5% cream during VC Period, continued applying ruxolitinib 1.5% cream topically to the affected areas as a thin film BID from Week 8 to 24 during the Vehicle Control Extension (VCE) Period. Participants stopped treatment 3 days after lesions disappeared and restarted at the first sign of recurrence.

    Drug: Ruxolitinib Cream

  • Placebo comparator
    VC Extension Period/Escape Arm: Vehicle Cream BID

    Participants who applied vehicle cream during the VC Period, continued applying vehicle cream as a thin film twice daily (BID) from Weeks 8 to 24 during the VCE Period. Participants applied cream BID to areas identified at Baseline even if the areas improved. Participants will be eligible to enter the ruxolitinib 1.5% cream open-label escape arm as defined in the protocol.

    Drug: Vehicle Cream

  • Experimental
    VC Extension Period: Ruxolitinib 1.5% cream open-label escape arm

    Participants received ruxolitinib 1.5% cream, applied topically to the affected areas as a thin film twice daily (BID) during the VCE Period. Participants applied cream BID to areas identified at Baseline even if the areas improved.

    Drug: Ruxolitinib Cream

Interventions

  • Ruxolitinib cream applied topically to the affected area as a thin film twice daily.

    Also known as: INCB018424 Phosphate Cream

  • DrugVehicle Cream

    Matching vehicle cream applied topically to the affected area as a thin film twice daily.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving a ≥75% Improvement in the Eczema Area and Severity Index Score (EASI75) at Week 8

    EASI75 was defined as achieving a ≥75% improvement in the EASI score compared to the baseline score. The EASI scoring system is a validated scoring system that grades the physical signs of atopic dermatitis (AD) to provide a measure of AD severity (ranging from 0 to 72). The disease severity strata for the EASI are: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe.

    Time frame: Baseline; Week 8

  2. Percentage of Participants With Investigator's Global Assessment Treatment Success (IGA-TS) at Week 8

    IGA-TS was defined as achieving an IGA score of 0 or 1 with a ≥2-grade improvement from baseline. The IGA is an overall eczema severity rating on a 0 to 4 scale. 0: clear; no erythema or induration/papulation, no oozing/crusting; there may be minor residual discoloration. 1: almost clear; may be trace faint pink erythema, with almost no induration/papulation, and no oozing/crusting. 2: mild; may be faint pink erythema, with mild induration/papulation and no oozing/crusting. 3: moderate; may be pink-red erythema with moderate induration/papulation and may be some oozing/crusting. 4: severe; may be deep or bright red erythema with severe induration/papulation and with oozing/crusting.

    Time frame: Baseline; Week 8

Secondary outcomes

  1. Percentage of Participants Achieving a ≥4-point Improvement in Itch Numeric Rating Scale (NRS) Score (ITCH4) From Baseline to Week 8

    ITCH4 is defined as achieving a ≥4-point improvement from baseline in Itch NRS score. The Itch NRS is a once-daily patient-reported measure of itch intensity assessed using an 11-point scale (0 = no itch to 10 = worst imaginable itch) that best describes their worst level of itching in the past 24 hours. The Itch NRS score for baseline was determined by averaging the 7 daily NRS scores directly before Day 1 (Day -7 to Day -1). The by-visit Itch NRS score for postbaseline visits was determined by averaging the 7 daily NRS scores directly before the visit day.

    Time frame: Baseline; Week 8

  2. Percentage of Participants Achieving ITCH4 From Baseline to Days 2, 3, and 7

    ITCH4 is defined as achieving a ≥4-point improvement from baseline in Itch NRS score. The Itch NRS is a once-daily patient-reported measure of itch intensity assessed using an 11-point scale (0 = no itch to 10 = worst imaginable itch) that best describes their worst level of itching in the past 24 hours. The Itch NRS score for baseline was determined by averaging the 7 daily NRS scores directly before Day 1 (Day -7 to Day -1). The by-visit Itch NRS score for postbaseline visits was determined by averaging the 7 daily NRS scores directly before the visit day.

    Time frame: Baseline; Days 2, 3, and 7

  3. Vehicle-controlled (VC) Period: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)

    An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study cream. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first application of study cream and no later than 30 days after the Week 24 or early termination visit.

    Time frame: up to Week 12

  4. Vehicle-controlled Extension Double-blind (VCE DB) Period: Number of Participants With Any TEAE

    An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study cream. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first application of study cream and no later than 30 days after the Week 24 or early termination visit.

    Time frame: up to 20 weeks (from Week 8 to Week 24 plus 30 days)

  5. VCE Escape Arm: Number of Participants With Any TEAE

    An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study cream. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first application of study cream and no later than 30 days after the Week 24 or early termination visit.

    Time frame: up to 150 days

  6. VC Period: Number of Participants With Any ≥Grade 3 TEAE

    An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first application of study cream and no later than 30 days after the Week 24 or early termination visit. The severity of TEAEs was assessed using Common Terminology Criteria for Adverse Events (CTCAE) v5.0 Grades 1-5. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.

    Time frame: up to Week 12

  7. VCE DB Period: Number of Participants With Any ≥Grade 3 TEAE

    An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first application of study cream and no later than 30 days after the Week 24 or early termination visit. The severity of TEAEs was assessed using CTCAE v5.0 Grades 1-5. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.

    Time frame: up to 20 weeks (from Week 8 to Week 24 plus 30 days)

  8. VCE Escape Arm: Number of Participants With Any ≥Grade 3 TEAE

    An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first application of study cream and no later than 30 days after the Week 24 or early termination visit. The severity of TEAEs was assessed using CTCAE v5.0 Grades 1-5. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.

    Time frame: up to 150 days

  9. Double-blind Treatment Period: Percentage of Participants Achieving EASI75 From Baseline at Weeks 2, 4, 12, 16, 20, and 24

    EASI75 was defined as achieving a ≥75% improvement in the EASI score compared to the baseline score. The EASI scoring system is a validated scoring system that grades the physical signs of atopic dermatitis (AD) to provide a measure of AD severity (ranging from 0 to 72). The disease severity strata for the EASI are: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe.

    Time frame: Baseline; Weeks 2, 4, 12, 16, 20, and 24

  10. VCE Escape Arm: Percentage of Participants Achieving EASI75 From Baseline at Weeks 12, 16, 20, and 24

    EASI75 was defined as achieving a ≥75% improvement in the EASI score compared to the baseline score. The EASI scoring system is a validated scoring system that grades the physical signs of atopic dermatitis (AD) to provide a measure of AD severity (ranging from 0 to 72). The disease severity strata for the EASI are: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe.

    Time frame: Baseline; Weeks 12, 16, 20, and 24

  11. Double-blind Treatment Period: Percentage of Participants With IGA-TS From Baseline at Each Postbaseline Visit Except Week 8

    IGA-TS was defined as achieving an IGA score of 0 or 1 with a ≥2-grade improvement from baseline. The IGA is an overall eczema severity rating on a 0 to 4 scale. 0: clear; no erythema or induration/papulation, no oozing/crusting; there may be minor residual discoloration. 1: almost clear; may be trace faint pink erythema, with almost no induration/papulation, and no oozing/crusting. 2: mild; may be faint pink erythema, with mild induration/papulation and no oozing/crusting. 3: moderate; may be pink-red erythema with moderate induration/papulation and may be some oozing/crusting. 4: severe; may be deep or bright red erythema with severe induration/papulation and with oozing/crusting.

    Time frame: Baseline; Weeks 2, 4, 12, 16, 20, and 24

  12. VCE Escape Arm: Percentage of Participants With IGA-TS From Baseline at Weeks 12, 16, 20, and 24

    IGA-TS was defined as achieving an IGA score of 0 or 1 with a ≥2-grade improvement from baseline. The IGA is an overall eczema severity rating on a 0 to 4 scale. 0: clear; no erythema or induration/papulation, no oozing/crusting; there may be minor residual discoloration. 1: almost clear; may be trace faint pink erythema, with almost no induration/papulation, and no oozing/crusting. 2: mild; may be faint pink erythema, with mild induration/papulation and no oozing/crusting. 3: moderate; may be pink-red erythema with moderate induration/papulation and may be some oozing/crusting. 4: severe; may be deep or bright red erythema with severe induration/papulation and with oozing/crusting.

    Time frame: Baseline; Weeks 12, 16, 20, and 24

  13. Percentage of Participants Achieving ITCH4 From Baseline to Weeks 2 and 4

    ITCH4 is defined as achieving a ≥4-point improvement from baseline in Itch NRS score. The Itch NRS is a once-daily patient-reported measure of itch intensity assessed using an 11-point scale (0 = no itch to 10 = worst imaginable itch) that best describes their worst level of itching in the past 24 hours. The Itch NRS score for baseline was determined by averaging the 7 daily NRS scores directly before Day 1 (Day -7 to Day -1). The by-visit Itch NRS score for postbaseline visits was determined by averaging the 7 daily NRS scores directly before the visit day.

    Time frame: Baseline; Weeks 2 and 4

  14. Time to Achieve ITCH4 During the VC Period

    ITCH4 is defined as achieving a ≥4-point improvement from baseline in Itch NRS score. The Itch NRS is a once-daily patient-reported measure of itch intensity assessed using an 11-point scale (0 = no itch to 10 = worst imaginable itch) that best describes their worst level of itching in the past 24 hours. The Itch NRS score for baseline was determined by averaging the 7 daily NRS scores directly before Day 1 (Day -7 to Day -1). The by-visit Itch NRS score for postbaseline visits was determined by averaging the 7 daily NRS scores directly before the visit day.

    Time frame: up to Week 8

  15. Time to Achieve ITCH2 During the VC Period

    ITCH2 is defined as achieving a ≥2-point improvement from baseline in Itch NRS score. The Itch NRS is a once-daily patient-reported measure of itch intensity assessed using an 11-point scale (0 = no itch to 10 = worst imaginable itch) that best describes their worst level of itching in the past 24 hours. The Itch NRS score for baseline was determined by averaging the 7 daily NRS scores directly before Day 1 (Day -7 to Day -1). The by-visit Itch NRS score for postbaseline visits was determined by averaging the 7 daily NRS scores directly before the visit day.

    Time frame: up to Week 8

  16. Change From Baseline (Pre-application) in Current Itch NRS Score at 5, 15, 30, 45, and 60 Minutes and 2, 4, and 6 Hours Post-initial Dose on Day 1

    The Itch NRS is a once-daily patient-reported measure of itch intensity assessed using an 11-point scale (0 = no itch to 10 = worst imaginable itch) that best describes their worst level of itching in the past 24 hours. The Itch NRS score for baseline was determined by averaging the 7 daily NRS scores directly before Day 1 (Day -7 to Day -1). The by-visit Itch NRS score for postbaseline visits was determined by averaging the 7 daily NRS scores directly before the visit day. Change from baseline was calculated as the post-baseline value minus the baseline value.

    Time frame: Baseline; Day 1

  17. Percentage of Participants Achieving at Least a 2-point Decrease From Baseline in Current Itch NRS Score at 5, 15, 30, 45, and 60 Minutes and 2, 4, and 6 Hours Post-Initial Dose on Day 1

    The Itch NRS is a once-daily patient-reported measure of itch intensity assessed using an 11-point scale (0 = no itch to 10 = worst imaginable itch) that best describes their worst level of itching in the past 24 hours. The Itch NRS score for baseline was determined by averaging the 7 daily NRS scores directly before Day 1 (Day -7 to Day -1). The by-visit Itch NRS score for postbaseline visits was determined by averaging the 7 daily NRS scores directly before the visit day.

    Time frame: Baseline; Day 1

  18. Percentage of Participants Achieving at Least a 4-point Decrease From Baseline in Current Itch NRS Score at 5, 15, 30, 45, and 60 Minutes and 2, 4, and 6 Hours Post-Initial Dose on Day 1

    The Itch NRS is a once-daily patient-reported measure of itch intensity assessed using an 11-point scale (0 = no itch to 10 = worst imaginable itch) that best describes their worst level of itching in the past 24 hours. The Itch NRS score for baseline was determined by averaging the 7 daily NRS scores directly before Day 1 (Day -7 to Day -1). The by-visit Itch NRS score for postbaseline visits was determined by averaging the 7 daily NRS scores directly before the visit day.

    Time frame: Baseline; Day 1

  19. Double-blind Treatment Period: Percentage of Participants Achieving EASI50 From Baseline at Weeks 2, 4, 8, 12, 16, 20, and 24

    EASI50 was defined as achieving a ≥50% improvement in the EASI score compared to the baseline score. The EASI scoring system is a validated scoring system that grades the physical signs of atopic dermatitis (AD) to provide a measure of AD severity (ranging from 0 to 72). The disease severity strata for the EASI are: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe.

    Time frame: Baseline; Weeks 2, 4, 8, 12, 16, 20, and 24

  20. Double-blind Treatment Period: Percentage of Participants With EASI90 From Baseline at Weeks 2, 4, 8, 12, 16, 20, and 24

    EASI90 was defined as achieving a ≥90% improvement in the EASI score compared to the baseline score. The EASI scoring system is a validated scoring system that grades the physical signs of atopic dermatitis (AD) to provide a measure of AD severity (ranging from 0 to 72). The disease severity strata for the EASI are: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe.

    Time frame: Baseline; Weeks 2, 4, 8, 12, 16, 20, and 24

  21. Double-blind Treatment Period: Percentage of Participants Achieving Both EASI75 and IGA-TS at Weeks 2, 4, 8, 12, 16, 20, and 24

    EASI75=a ≥75% improvement in the EASI score compared to the baseline score. The EASI scoring system grades the physical signs of AD to provide a measure of severity (range=0-72). EASI disease severity strata: 0 = clear; 0.1-1.0 = almost clear; 1.1-7.0 = mild; 7.1-21.0 = moderate; 21.1-50.0 = severe; 50.1 to 72.0 = very severe. IGA-TS = an IGA score of 0 or 1 with a ≥2-grade improvement from baseline. The IGA is an overall eczema severity rating on a 0 to 4 scale. 0: clear; no erythema or induration/papulation, no oozing/crusting; there may be minor residual discoloration. 1: almost clear; may be trace faint pink erythema, with almost no induration/papulation, and no oozing/crusting. 2: mild; may be faint pink erythema, with mild induration/papulation and no oozing/crusting. 3: moderate; may be pink-red erythema with moderate induration/papulation and may be some oozing/crusting. 4: severe; may be deep or bright red erythema with severe induration/papulation and with oozing/crusting.

    Time frame: Baseline; Weeks 2, 4, 8, 12, 16, 20, and 24

  22. Change From Baseline for Atopic Dermatitis-affected %Body Surface Area (BSA) at Weeks 2, 4, and 8 of the Double-blind Treatment Period

    BSA assessment was approximated to the nearest 0.1% using the handprint (Palmar) method as a guide. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits, with fingers tucked together and thumb tucked to the side) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Change from baseline was calculated as the post-baseline value minus the baseline value.

    Time frame: Baseline; Weeks 2, 4, and 8

  23. Change From Baseline for Atopic Dermatitis-affected %BSA at Weeks 12, 16, 20, and 24 of the Double-blind Treatment Period

    BSA assessment was approximated to the nearest 0.1% using the handprint (Palmar) method as a guide. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits, with fingers tucked together and thumb tucked to the side) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Change from baseline was calculated as the post-baseline value minus the baseline value.

    Time frame: Baseline; Weeks 12, 16, 20, and 24

  24. Change From Baseline for the EASI Score at Weeks 2, 4, and 8 of the Double-blind Treatment Period

    The EASI scoring system is a validated scoring system that grades the physical signs of atopic dermatitis (AD) to provide a measure of AD severity (ranging from 0 to 72). The disease severity strata for the EASI are: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. Change from baseline was calculated as the post-baseline value minus the baseline value.

    Time frame: Baseline; Weeks 2, 4, and 8

  25. Change From Baseline for the EASI Score at Weeks 12, 16, 20, and 24 of the Double-blind Treatment Period

    The EASI scoring system is a validated scoring system that grades the physical signs of atopic dermatitis (AD) to provide a measure of AD severity (ranging from 0 to 72). The disease severity strata for the EASI are: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. Change from baseline was calculated as the post-baseline value minus the baseline value.

    Time frame: Baseline; Weeks 12, 16, 20, and 24

  26. Change From Baseline for the SCORing Atopic Dermatitis (SCORAD) Score at Weeks 2, 4, and 8 of the Double-blind Treatment Period

    The SCORAD assesses the extent and severity (intensity) of eczema. To determine extent, the rule of 9 or handprint method was used to calculate the eczema affected area (A) as a percentage of the whole body. Scores were added to give a possible maximum of 100%. To determine intensity, a representative area of eczema was selected. The intensity of redness, swelling, oozing/crusting, scratch marks, skin thickening (lichenification), dryness was assessed individually: none, 0; mild, 1; moderate, 2; severe, 3. Intensity scores were added together to give "B" (maximum score of 18). Subjective symptoms (itch and sleeplessness) were scored by the participant using a visual analog scale on which "0" was no itch (or no sleeplessness) and "10" was the worst imaginable itch (or sleeplessness). These scores were added to give "C" (maximum score of 20). The total score\[KM25.1\] (ranging from 0 to 103; a higher score indicates greater extent and severity) was calculated as: A/5 + 7B/2 + C.

    Time frame: Baseline; Weeks 2, 4, and 8

  27. Change From Baseline for the SCORAD Score at Weeks 12, 16, 20, and 24 of the Double-blind Treatment Period

    The SCORAD assesses the extent and severity (intensity) of eczema. To determine extent, the rule of 9 or handprint method was used to calculate the eczema affected area (A) as a percentage of the whole body. Scores were added to give a possible maximum of 100%. To determine intensity, a representative area of eczema was selected. The intensity of redness, swelling, oozing/crusting, scratch marks, skin thickening (lichenification), dryness was assessed individually: none, 0; mild, 1; moderate, 2; severe, 3. Intensity scores were added together to give "B" (maximum score of 18). Subjective symptoms (itch and sleeplessness) were scored by the participant using a visual analog scale on which "0" was no itch (or no sleeplessness) and "10" was the worst imaginable itch (or sleeplessness). These scores were added to give "C" (maximum score of 20). The total score\[KM27.1\] (ranging from 0 to 103; a higher score indicates greater extent and severity) was calculated as: A/5 + 7B/2 + C.

    Time frame: Baseline; Weeks 12, 16, 20, and 24

  28. Change From Baseline for Itch NRS Score at Days 1 Through 56 (8 Weeks)

    The Itch NRS is a once-daily patient-reported measure of itch intensity assessed using an 11-point scale (0 = no itch to 10 = worst imaginable itch) that best describes their worst level of itching in the past 24 hours. The Itch NRS score for baseline was determined by averaging the 7 daily NRS scores directly before Day 1 (Day -7 to Day -1). The by-visit Itch NRS score for postbaseline visits was determined by averaging the 7 daily NRS scores directly before the visit day. Change from baseline was calculated as the post-baseline value minus the baseline value.

    Time frame: Baseline; Days 1 through 56 (8 weeks)

  29. Change From Baseline for Skin Pain NRS Score at Weeks 2, 4, and 8 of the Double-blind Treatment Period

    The Skin Pain NRS is a daily participant-reported measure (24-hour or 7-day recall) of the worst level of pain intensity from 0 (no pain) to 10 (worst pain imaginable). Participants were asked to rate the pain intensity by selecting a number that best describes the worst level of pain in the past 24 hours during the VC period and in the past 7 days during the VCE period. Change from baseline was calculated as the post-baseline value minus the baseline value.

    Time frame: Baseline; Weeks 2, 4, and 8

  30. Skin Pain NRS Score at Weeks 12, 16, 20, and 24 of the Double-blind Treatment Period

    The Skin Pain NRS is a daily participant-reported measure (24-hour or 7-day recall) of the worst level of pain intensity from 0 (no pain) to 10 (worst pain imaginable). Participants were asked to rate the pain intensity by selecting a number that best describes the worst level of pain in the past 24 hours during the VC period and in the past 7 days during the VCE period.

    Time frame: Baseline; Weeks 12, 16, 20, and 24

  31. Time to Open-label Escape Arm

    The study allowed participants to move to an open-label ruxolitinib 1.5% escape arm if they had not met EASI50 (50% improvement in the EASI score from baseline at 2 consecutive visits at least 1 week apart) at Week 8 (end of the double-blind, vehicle-controlled period and the start of the vehicle-controlled extension, double-blind period) or if they lost EASI50 response during the vehicle-controlled extension, double-blind period. Participants who were moved to the open-label ruxolitinib 1.5% escape arm without meeting the criteria were censored.

    Time frame: up to 16 weeks (from Week 8 to Week 24)

  32. Percentage of Participants in the VCE DB Period Concurrently Meeting All of the Following Criteria: IGA Score ≥3, EASI Score ≥16, Itch NRS Score, ≥4, BSA ≥10%, and Dermatology Life Quality Index (DLQI) Score >10

    Only data in the DB treatment period were included in the analysis.

    Time frame: up to 16 weeks (from Week 8 to Week 24)

  33. Time to Participants in the VCE DB Period Concurrently Meeting All of the Following Criteria: IGA Score ≥3, EASI Score ≥16, Itch NRS Score ≥4, BSA ≥10%, and DLQI Score >10

    Only data in the DB treatment period were included in the analysis.

    Time frame: up to 16 weeks (from Week 8 to Week 24)

  34. Percentage of Participants Who Experienced a Relapse After Study Treatment Discontinuation

    Relapse was assessed during the 30-day Safety Follow-up Period for participants who had an EASI75 response from baseline at the end of the VCE DB period at Week 24. Participants who experienced a relapse were those among EASI75 responders who were on study treatment at Week 24 who met relapse criteria (loss of EASI50 from baseline) at the safety follow-up visit.

    Time frame: up to 30 days following Week 24

  35. Time to First Retreatment During the VCE DB Period

    Time to first retreatment following the participant's first lesion clearance during the VCE DB period was evaluated in participants who had at least 1 occurrence of lesion clearance.

    Time frame: up to 16 weeks (from Week 8 to Week 24)

  36. Percentage of Time Off Study Treatment Due to Lesion Clearance During the VCE DB Period

    The percentage of time off study treatment was calculated as the total days off study treatment due to lesion clearance divided by the total days between two visits per participant.

    Time frame: from Week 8 to Week 12; from Week 12 to Week 16; from Week 16 to Week 20; from Week 20 to Week 24

  37. Percentage of Time on Study Treatment During the VCE DB Period

    The percentage of time on study treatment was calculated as the total days intended on study treatment divided by the total days between two visits per participant.

    Time frame: from Week 8 to Week 12; from Week 12 to Week 16; from Week 16 to Week 20; from Week 20 to Week 24

  38. Double-blind Treatment Period: Percentage of Participants Who Achieved a ≥4-point Improvement in Dermatology Life Quality Index (DLQI) From Baseline at Weeks 2, 4, 8, 12, 16, 20, and 24

    The DLQI is 10-question validated questionnaire measuring how much the skin problem has affected the participant over the previous 7 days. The questionnaire is analyzed under 6 headings: symptoms and feelings (Questions 1 and 2); daily activities (Questions 3 and 4); leisure (Questions 5 and 6); work and school (Question 7); personal relations (Questions 8 and 9); treatment (Question 10). The scoring of each question is: 3, very much; 2, a lot; 1, a little; 0, not at all; not relevant, 0; Question 7, "prevented work or studying," 3. The DLQI is calculated by summing the scores of each question, resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired. Total DLQI scores can be categorized as: 0-1, no effect; 2-5, small effect; 6-10, moderate effect; 11-20, very large effect; 21-30, extremely large effect.

    Time frame: Baseline; Weeks 2, 4, 12, 16, 20, and 24

  39. Change From Baseline in the DLQI Score at Weeks 2, 4, and 8 of the Double-blind Treatment Period

    The DLQI is 10-question validated questionnaire measuring how much the skin problem has affected the participant over the previous 7 days. The questionnaire is analyzed under 6 headings: symptoms and feelings (Questions 1 and 2); daily activities (Questions 3 and 4); leisure (Questions 5 and 6); work and school (Question 7); personal relations (Questions 8 and 9); treatment (Question 10). The scoring of each question is: 3, very much; 2, a lot; 1, a little; 0, not at all; not relevant, 0; Question 7, "prevented work or studying," 3. The DLQI is calculated by summing the scores of each question, resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired. Total DLQI scores can be categorized as: 0-1, no effect; 2-5, small effect; 6-10, moderate effect; 11-20, very large effect; 21-30, extremely large effect. Change from baseline was calculated as the post-baseline value minus the baseline value.

    Time frame: Baseline; Weeks 2, 4, and 8

  40. Change From Baseline in the DLQI Score at Weeks 12, 16, 20, and 24 of the Double-blind Treatment Period

    The DLQI is 10-question validated questionnaire measuring how much the skin problem has affected the participant over the previous 7 days. The questionnaire is analyzed under 6 headings: symptoms and feelings (Questions 1 and 2); daily activities (Questions 3 and 4); leisure (Questions 5 and 6); work and school (Question 7); personal relations (Questions 8 and 9); treatment (Question 10). The scoring of each question is: 3, very much; 2, a lot; 1, a little; 0, not at all; not relevant, 0; Question 7, "prevented work or studying," 3. The DLQI is calculated by summing the scores of each question, resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired. Total DLQI scores can be categorized as: 0-1, no effect; 2-5, small effect; 6-10, moderate effect; 11-20, very large effect; 21-30, extremely large effect. Change from baseline was calculated as the post-baseline value minus the baseline value.

    Time frame: Baseline; Weeks 12, 16, 20, and 24

  41. Change From Baseline in the Patient-oriented Eczema Measure (POEM) Score at Weeks 2, 4, and 8 of the Double-blind Treatment Period

    The POEM is a 7-question quality-of-life assessment used for monitoring atopic eczema severity, focusing on the illness as experienced by the participant. The questionnaire asks how many days the participant has been bothered by various aspects of their skin condition during the past week. The response options and corresponding scoring questionnaires are: no days (0), 1 to 2 days (1), 3 to 4 days (2), 5 to 6 days (3), and every day (4), with total scores ranging from 0 to 28. The meaning of POEM scores can be categorized as: 0 to 2 (clear/almost clear), 3 to 7 (mild eczema), 8 to 16 (moderate eczema), 17 to 24 (severe eczema), and 25 to 28 (very severe eczema). Change from baseline was calculated as the post-baseline value minus the baseline value.

    Time frame: Baseline; Weeks 2, 4, and 8

  42. Change From Baseline in the POEM Score at Weeks 12, 16, 20, and 24 of the Double-blind Treatment Period

    The POEM is a 7-question quality-of-life assessment used for monitoring atopic eczema severity, focusing on the illness as experienced by the participant. The questionnaire asks how many days the participant has been bothered by various aspects of their skin condition during the past week. The response options and corresponding scoring questionnaires are: no days (0), 1 to 2 days (1), 3 to 4 days (2), 5 to 6 days (3), and every day (4), with a range in total score of 0 to 28. The meaning of POEM scores can be categorized as: 0 to 2 (clear/almost clear), 3 to 7 (mild eczema), 8 to 16 (moderate eczema), 17 to 24 (severe eczema), and 25 to 28 (very severe eczema). Change from baseline was calculated as the post-baseline value minus the baseline value.

    Time frame: Baseline; Weeks 12, 16, 20, and 24

  43. Change From Baseline in the EQ-5D-5L Visual Analog Scale Score at Weeks 2, 4, and 8 of the Double-blind Treatment Period

    The EQ-5D is a validated, self-administered, generic utility questionnaire wherein participants rate their current health state based on the following criteria (dimensions): mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The 5L indicates that, for each dimension, there are 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The participant was asked to indicate his/her health state over the past 7 days using a scale ranging from 0 (worst imaginable health) to 100 (best imaginable health). Missing values were not imputed. Change from Baseline was calculated as the post-baseline value minus the baseline value.

    Time frame: Baseline; Weeks 2, 4, and 8

  44. Change From Baseline in the EQ-5D-5L Visual Analog Scale Score at Weeks 12, 16, 20, and 24 of the Double-blind Treatment Period

    The EQ-5D is a validated, self-administered, generic utility questionnaire wherein participants rate their current health state based on the following criteria (dimensions): mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The 5L indicates that, for each dimension, there are 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The participant was asked to indicate his/her health state over the past 7 days using a scale ranging from 0 (worst imaginable health) to 100 (best imaginable health). Missing values were not imputed. Change from Baseline was calculated as the post-baseline value minus the baseline value.

    Time frame: Baseline; Weeks 12, 16, 20, and 24

  45. Change From Baseline in the Hospital Anxiety and Depression Scale (HADS) Score at Weeks 2, 4, and 8 of the Double-blind Treatment Period

    The HADS is a 14-item questionnaire that assesses the levels of anxiety and depression a person is currently experiencing. There are 7 questions each for measuring anxiety and for measuring depression, with 4 possible responses to each question: 0, 1, 2, or 3. Separate scores were calculated for anxiety and depression, both ranging from 0 to 21; a higher score indicates a greater level of anxiety/depression. The recall period was the past 7 days for both the VC and VCE periods. Change from baseline was calculated as the post-baseline value minus the baseline value.

    Time frame: Baseline; Weeks 2, 4, and 8

  46. Change From Baseline in the HADS Score at Weeks 12, 16, 20, and 24 of the Double-blind Treatment Period

    The HADS is a 14-item questionnaire that assesses the levels of anxiety and depression a person is currently experiencing. There are 7 questions each for measuring anxiety and for measuring depression, with 4 possible responses to each question: 0, 1, 2, or 3. Separate scores were calculated for anxiety and depression, both ranging from 0 to 21; a higher score indicates a greater level of anxiety/depression. The recall period was the past 7 days for both the VC and VCE periods. Change from baseline was calculated as the post-baseline value minus the baseline value.

    Time frame: Baseline; Weeks 12, 16, 20, and 24

  47. Change From Baseline in the Patient-Reported Outcomes Measurement Information System (PROMIS) Short Form - Sleep-Related Impairment (8a: 7-day Recall) Score at Weeks 2, 4, and 8

    The PROMIS Short Form - Sleep-Related Impairment (8a) is an 8-item questionnaire. Each item is rated on a 5-point scale (never, almost never, sometimes, almost always, and always). Individual items are summed to get a total score ranging from 8 to 40; higher scores indicate greater severity of sleep-related impairment. The recall period was 7 days. Change from baseline was calculated as the post-baseline value minus the baseline value.

    Time frame: Baseline; Weeks 2, 4, and 8

  48. Change From Baseline in the PROMIS Short Form - Sleep-Related Impairment (8a: 7-day Recall) Score at Weeks 12, 16, 20, and 24

    The PROMIS Short Form - Sleep-Related Impairment (8a) is an 8-item questionnaire. Each item is rated on a 5-point scale (never, almost never, sometimes, almost always, and always). Individual items are summed to get a total score ranging from 8 to 40; higher scores indicate greater severity of sleep-related impairment. The recall period was 7 days. Change from baseline was calculated as the post-baseline value minus the baseline value.

    Time frame: Baseline; Weeks 12, 16, 20, and 24

  49. Change From Baseline in the PROMIS Short Form - Sleep Disturbance (8b: 7-day Recall) Score at Weeks 2, 4, and 8

    The PROMIS Short Form - Sleep-Related Disturbance (8b) is an 8-item questionnaire. Each item is rated on a 5-point scale (never, almost never, sometimes, almost always, and always). Individual items are summed to get a total score ranging from 8 to 40; higher scores indicate greater severity of sleep-related disturbance. The recall period was 7 days. Change from baseline was calculated as the post-baseline value minus the baseline value.

    Time frame: Baseline; Weeks 2, 4, and 8

  50. Change From Baseline in the PROMIS Short Form - Sleep Disturbance (8b: 7-day Recall) Score at Weeks 12, 16, 20, and 24

    The PROMIS Short Form - Sleep-Related Disturbance (8b) is an 8-item questionnaire. Each item is rated on a 5-point scale (never, almost never, sometimes, almost always, and always). Individual items are summed to get a total score ranging from 8 to 40; higher scores indicate greater severity of sleep-related disturbance. The recall period was 7 days. Change from baseline was calculated as the post-baseline value minus the baseline value.

    Time frame: Baseline; Weeks 12, 16, 20, and 24

  51. Change From Baseline in the Work Productivity and Activity Impairment Questionairre-Atopic Dermatitis (WPAI-AD) Score at Weeks 8 and 24

    The WPAI-AD questionnaire is a validated 6-item instrument that measures the effect of overall health and specific symptoms on productivity at work and regular activities outside of it during the past 7 days. The WPAI outcomes are expressed as impairment percentages (0% to 100% for all outcomes; higher number indicate greater impairment and less productivity \[i.e., worse outcomes\]): Questions: 1 = currently employed; 2 = hours missed due to AD; 3 = hours missed other reasons; 4 = hours actually worked; 5 = degree AD-affected productivity while working; 6 = degree AD-affected regular activities. Scores: multiply scores by 100 to express in percentages: percent work time missed due to AD: Q2 / (Q2 + Q4); percent impairment while working due to AD: Q5 / 10; percent overall work impairment due to AD: Q2 / (Q2 + Q4) + (\[1 - (Q2 / (Q2+Q4)\] × \[Q5/10\]); percent activity impairment due to AD: Q6 / 10. Change from baseline was calculated as the post-baseline value minus the baseline value.

    Time frame: Baseline; Weeks 8 and 24

07

Results

Posted May 22, 2026

Participant flow

Blinded-Treatment 8-Week VC Period
Participant flow — Blinded-Treatment 8-Week VC Period
MilestoneVehicle CreamRuxolitinib 1.5% CreamVehicle Cream to Ruxolitinib 1.5% CreamRuxolitinib 1.5% Cream to Ruxolitinib 1.5% Cream
Started8116000
Entered escape arm at week 8403200
Completed6015400
Not completed21600
Withdrew: Adverse event7100
Withdrew: Death1000
Withdrew: Lack of efficacy4200
Withdrew: Protocol violation1000
Withdrew: Withdrawal by subject8100
Withdrew: Unable to comply with study visit requirements0100
Withdrew: Non-compliance0100
Blinded-Treatment 16-Week VCE DB Period
Participant flow — Blinded-Treatment 16-Week VCE DB Period
MilestoneVehicle CreamRuxolitinib 1.5% CreamVehicle Cream to Ruxolitinib 1.5% CreamRuxolitinib 1.5% Cream to Ruxolitinib 1.5% Cream
Started2012100
Entered escape arm during vce db period61400
Completed1911400
Not completed1700
Withdrew: Lost to follow-up1400
Withdrew: Withdrawal by subject0200
Withdrew: Pregnancy0100
Open-Label Escape
Participant flow — Open-Label Escape
MilestoneVehicle CreamRuxolitinib 1.5% CreamVehicle Cream to Ruxolitinib 1.5% CreamRuxolitinib 1.5% Cream to Ruxolitinib 1.5% Cream
Started004646
Completed004138
Not completed0058
Withdrew: Lack of efficacy0002
Withdrew: Withdrawal by subject0045
Withdrew: Lost to follow-up0010
Withdrew: Inadvertently enrolled in escape arm0001

Outcome measures

PrimaryPercentage of Participants Achieving a ≥75% Improvement in the Eczema Area and Severity Index Score (EASI75) at Week 8

EASI75 was defined as achieving a ≥75% improvement in the EASI score compared to the baseline score. The EASI scoring system is a validated scoring system that grades the physical signs of atopic dermatitis (AD) to provide a measure of AD severity (ranging from 0 to 72). The disease severity strata for the EASI are: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe.

Time frame:
Baseline; Week 8
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a ≥75% Improvement in the Eczema Area and Severity Index Score (EASI75) at Week 8
percentage of participantsVehicle CreamRuxolitinib 1.5% Cream
Percentage of Participants Achieving a ≥75% Improvement in the Eczema Area and Severity Index Score (EASI75) at Week 818.5 (10.8 to 28.7)70.0 (62.3 to 77.0)
Statistical analysis
  • Vehicle Cream vs Ruxolitinib 1.5% Cream · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 11.26 · 95% CI 5.692 to 22.260stratified by baseline EASI score and geographic region
PrimaryPercentage of Participants With Investigator's Global Assessment Treatment Success (IGA-TS) at Week 8

IGA-TS was defined as achieving an IGA score of 0 or 1 with a ≥2-grade improvement from baseline. The IGA is an overall eczema severity rating on a 0 to 4 scale. 0: clear; no erythema or induration/papulation, no oozing/crusting; there may be minor residual discoloration. 1: almost clear; may be trace faint pink erythema, with almost no induration/papulation, and no oozing/crusting. 2: mild; may be faint pink erythema, with mild induration/papulation and no oozing/crusting. 3: moderate; may be pink-red erythema with moderate induration/papulation and may be some oozing/crusting. 4: severe; may be deep or bright red erythema with severe induration/papulation and with oozing/crusting.

Time frame:
Baseline; Week 8
Reported as:
Number · percentage of participants
Percentage of Participants With Investigator's Global Assessment Treatment Success (IGA-TS) at Week 8
percentage of participantsVehicle CreamRuxolitinib 1.5% Cream
Percentage of Participants With Investigator's Global Assessment Treatment Success (IGA-TS) at Week 813.6 (7.0 to 23.0)61.3 (53.2 to 68.8)
Statistical analysis
  • Vehicle Cream vs Ruxolitinib 1.5% Cream · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 10.14 · 95% CI 4.904 to 20.975stratified by baseline EASI score and geographic region
SecondaryPercentage of Participants Achieving a ≥4-point Improvement in Itch Numeric Rating Scale (NRS) Score (ITCH4) From Baseline to Week 8

ITCH4 is defined as achieving a ≥4-point improvement from baseline in Itch NRS score. The Itch NRS is a once-daily patient-reported measure of itch intensity assessed using an 11-point scale (0 = no itch to 10 = worst imaginable itch) that best describes their worst level of itching in the past 24 hours. The Itch NRS score for baseline was determined by averaging the 7 daily NRS scores directly before Day 1 (Day -7 to Day -1). The by-visit Itch NRS score for postbaseline visits was determined by averaging the 7 daily NRS scores directly before the visit day.

Time frame:
Baseline; Week 8
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a ≥4-point Improvement in Itch Numeric Rating Scale (NRS) Score (ITCH4) From Baseline to Week 8
percentage of participantsVehicle CreamRuxolitinib 1.5% Cream
Percentage of Participants Achieving a ≥4-point Improvement in Itch Numeric Rating Scale (NRS) Score (ITCH4) From Baseline to Week 819.8 (11.7 to 30.1)62.5 (54.5 to 70.0)
Statistical analysis
  • Vehicle Cream vs Ruxolitinib 1.5% Cream · Cochran-Mantel-Haenszel · p = 0.0001 · Odds ratio (or): 6.99 · 95% CI 3.675 to 13.314stratified by baseline EASI score and geographic region
SecondaryPercentage of Participants Achieving ITCH4 From Baseline to Days 2, 3, and 7

ITCH4 is defined as achieving a ≥4-point improvement from baseline in Itch NRS score. The Itch NRS is a once-daily patient-reported measure of itch intensity assessed using an 11-point scale (0 = no itch to 10 = worst imaginable itch) that best describes their worst level of itching in the past 24 hours. The Itch NRS score for baseline was determined by averaging the 7 daily NRS scores directly before Day 1 (Day -7 to Day -1). The by-visit Itch NRS score for postbaseline visits was determined by averaging the 7 daily NRS scores directly before the visit day.

Time frame:
Baseline; Days 2, 3, and 7
Reported as:
Number · percentage of participants
Percentage of Participants Achieving ITCH4 From Baseline to Days 2, 3, and 7
percentage of participantsVehicle CreamRuxolitinib 1.5% Cream
Day 213.6729.75
Day 39.8835.09
Day 713.8651.20
Statistical analysis
  • Vehicle Cream vs Ruxolitinib 1.5% Cream · Cochran-Mantel-Haenszel · p = 0.0072 (stratified by baseline EASI score and geographic region) · Odds ratio (or): 2.7 · 95% CI 1.31 to 5.51stratified by baseline EASI score and geographic region; computed by applying Rubin's rule
  • Vehicle Cream vs Ruxolitinib 1.5% Cream · Cochran-Mantel-Haenszel · p = <0.0001 (stratified by baseline EASI score and geographic region) · Odds ratio (or): 5.4 · 95% CI 2.37 to 12.35stratified by baseline EASI score and geographic region; computed by applying Rubin's rule
  • Vehicle Cream vs Ruxolitinib 1.5% Cream · Cochran-Mantel-Haenszel · p = <0.0001 (stratified by baseline EASI score and geographic region) · Odds ratio (or): 6.8 · 95% CI 3.31 to 14.02stratified by baseline EASI score and geographic region; computed by applying Rubin's rule
SecondaryVehicle-controlled (VC) Period: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)

An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study cream. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first application of study cream and no later than 30 days after the Week 24 or early termination visit.

Time frame:
up to Week 12
Reported as:
Count of participants · Participants
Vehicle-controlled (VC) Period: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)
ParticipantsVehicle CreamRuxolitinib 1.5% Cream
Vehicle-controlled (VC) Period: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)2956
SecondaryVehicle-controlled Extension Double-blind (VCE DB) Period: Number of Participants With Any TEAE

An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study cream. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first application of study cream and no later than 30 days after the Week 24 or early termination visit.

Time frame:
up to 20 weeks (from Week 8 to Week 24 plus 30 days)
Reported as:
Count of participants · Participants
Vehicle-controlled Extension Double-blind (VCE DB) Period: Number of Participants With Any TEAE
ParticipantsVehicle CreamRuxolitinib 1.5% Cream
Vehicle-controlled Extension Double-blind (VCE DB) Period: Number of Participants With Any TEAE543
SecondaryVCE Escape Arm: Number of Participants With Any TEAE

An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study cream. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first application of study cream and no later than 30 days after the Week 24 or early termination visit.

Time frame:
up to 150 days
Reported as:
Count of participants · Participants
VCE Escape Arm: Number of Participants With Any TEAE
ParticipantsVehicle Cream to Ruxolitinib 1.5% CreamRuxolitinib 1.5% Cream
VCE Escape Arm: Number of Participants With Any TEAE1411
SecondaryVC Period: Number of Participants With Any ≥Grade 3 TEAE

An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first application of study cream and no later than 30 days after the Week 24 or early termination visit. The severity of TEAEs was assessed using Common Terminology Criteria for Adverse Events (CTCAE) v5.0 Grades 1-5. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.

Time frame:
up to Week 12
Reported as:
Count of participants · Participants
VC Period: Number of Participants With Any ≥Grade 3 TEAE
ParticipantsVehicle CreamRuxolitinib 1.5% Cream
VC Period: Number of Participants With Any ≥Grade 3 TEAE15
SecondaryVCE DB Period: Number of Participants With Any ≥Grade 3 TEAE

An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first application of study cream and no later than 30 days after the Week 24 or early termination visit. The severity of TEAEs was assessed using CTCAE v5.0 Grades 1-5. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.

Time frame:
up to 20 weeks (from Week 8 to Week 24 plus 30 days)
Reported as:
Count of participants · Participants
VCE DB Period: Number of Participants With Any ≥Grade 3 TEAE
ParticipantsVehicle CreamRuxolitinib 1.5% Cream
VCE DB Period: Number of Participants With Any ≥Grade 3 TEAE01
SecondaryVCE Escape Arm: Number of Participants With Any ≥Grade 3 TEAE

An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first application of study cream and no later than 30 days after the Week 24 or early termination visit. The severity of TEAEs was assessed using CTCAE v5.0 Grades 1-5. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.

Time frame:
up to 150 days
Reported as:
Count of participants · Participants
VCE Escape Arm: Number of Participants With Any ≥Grade 3 TEAE
ParticipantsVehicle Cream to Ruxolitinib 1.5% CreamRuxolitinib 1.5% Cream
VCE Escape Arm: Number of Participants With Any ≥Grade 3 TEAE00
SecondaryDouble-blind Treatment Period: Percentage of Participants Achieving EASI75 From Baseline at Weeks 2, 4, 12, 16, 20, and 24

EASI75 was defined as achieving a ≥75% improvement in the EASI score compared to the baseline score. The EASI scoring system is a validated scoring system that grades the physical signs of atopic dermatitis (AD) to provide a measure of AD severity (ranging from 0 to 72). The disease severity strata for the EASI are: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe.

Time frame:
Baseline; Weeks 2, 4, 12, 16, 20, and 24
Reported as:
Number · percentage of participants
Double-blind Treatment Period: Percentage of Participants Achieving EASI75 From Baseline at Weeks 2, 4, 12, 16, 20, and 24
percentage of participantsVehicle CreamRuxolitinib 1.5% Cream
Week 23.7 (0.8 to 10.4)43.8 (35.9 to 51.8)
Week 412.3 (6.1 to 21.5)61.3 (53.2 to 68.8)
Week 1288.9 (65.3 to 98.6)81.5 (73.4 to 88.0)
Week 1678.6 (49.2 to 95.3)85.6 (77.6 to 91.5)
Week 2071.4 (41.9 to 91.6)85.7 (77.5 to 91.8)
Week 2484.6 (54.6 to 98.1)84.5 (76.0 to 90.9)
SecondaryVCE Escape Arm: Percentage of Participants Achieving EASI75 From Baseline at Weeks 12, 16, 20, and 24

EASI75 was defined as achieving a ≥75% improvement in the EASI score compared to the baseline score. The EASI scoring system is a validated scoring system that grades the physical signs of atopic dermatitis (AD) to provide a measure of AD severity (ranging from 0 to 72). The disease severity strata for the EASI are: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe.

Time frame:
Baseline; Weeks 12, 16, 20, and 24
Reported as:
Number · percentage of participants
VCE Escape Arm: Percentage of Participants Achieving EASI75 From Baseline at Weeks 12, 16, 20, and 24
percentage of participantsVehicle Cream to Ruxolitinib 1.5% CreamRuxolitinib 1.5% Cream
Week 1250.0 (33.4 to 66.6)37.9 (20.7 to 57.7)
Week 1664.9 (47.5 to 79.8)44.8 (26.4 to 64.3)
Week 2070.3 (53.0 to 84.1)57.1 (37.2 to 75.5)
Week 2470.3 (53.0 to 84.1)60.7 (40.6 to 78.5)
SecondaryDouble-blind Treatment Period: Percentage of Participants With IGA-TS From Baseline at Each Postbaseline Visit Except Week 8

IGA-TS was defined as achieving an IGA score of 0 or 1 with a ≥2-grade improvement from baseline. The IGA is an overall eczema severity rating on a 0 to 4 scale. 0: clear; no erythema or induration/papulation, no oozing/crusting; there may be minor residual discoloration. 1: almost clear; may be trace faint pink erythema, with almost no induration/papulation, and no oozing/crusting. 2: mild; may be faint pink erythema, with mild induration/papulation and no oozing/crusting. 3: moderate; may be pink-red erythema with moderate induration/papulation and may be some oozing/crusting. 4: severe; may be deep or bright red erythema with severe induration/papulation and with oozing/crusting.

Time frame:
Baseline; Weeks 2, 4, 12, 16, 20, and 24
Reported as:
Number · percentage of participants
Double-blind Treatment Period: Percentage of Participants With IGA-TS From Baseline at Each Postbaseline Visit Except Week 8
percentage of participantsVehicle CreamRuxolitinib 1.5% Cream
Week 22.5 (0.3 to 8.6)29.4 (22.4 to 37.1)
Week 49.9 (4.4 to 18.5)48.8 (40.8 to 56.8)
Week 1261.1 (35.7 to 82.7)65.5 (56.3 to 74.0)
Week 1671.4 (41.9 to 91.6)64.9 (55.2 to 73.7)
Week 2064.3 (35.1 to 87.2)68.6 (58.8 to 77.3)
Week 2469.2 (38.6 to 90.9)70.9 (61.1 to 79.4)
SecondaryVCE Escape Arm: Percentage of Participants With IGA-TS From Baseline at Weeks 12, 16, 20, and 24

IGA-TS was defined as achieving an IGA score of 0 or 1 with a ≥2-grade improvement from baseline. The IGA is an overall eczema severity rating on a 0 to 4 scale. 0: clear; no erythema or induration/papulation, no oozing/crusting; there may be minor residual discoloration. 1: almost clear; may be trace faint pink erythema, with almost no induration/papulation, and no oozing/crusting. 2: mild; may be faint pink erythema, with mild induration/papulation and no oozing/crusting. 3: moderate; may be pink-red erythema with moderate induration/papulation and may be some oozing/crusting. 4: severe; may be deep or bright red erythema with severe induration/papulation and with oozing/crusting.

Time frame:
Baseline; Weeks 12, 16, 20, and 24
Reported as:
Number · percentage of participants
VCE Escape Arm: Percentage of Participants With IGA-TS From Baseline at Weeks 12, 16, 20, and 24
percentage of participantsVehicle Cream to Ruxolitinib 1.5% CreamRuxolitinib 1.5% Cream
Week 1239.5 (24.0 to 56.6)34.5 (17.9 to 54.3)
Week 1651.4 (34.4 to 68.1)37.9 (20.7 to 57.7)
Week 2059.5 (42.1 to 75.2)46.4 (27.5 to 66.1)
Week 2462.2 (44.8 to 77.5)46.4 (27.5 to 66.1)
SecondaryPercentage of Participants Achieving ITCH4 From Baseline to Weeks 2 and 4

ITCH4 is defined as achieving a ≥4-point improvement from baseline in Itch NRS score. The Itch NRS is a once-daily patient-reported measure of itch intensity assessed using an 11-point scale (0 = no itch to 10 = worst imaginable itch) that best describes their worst level of itching in the past 24 hours. The Itch NRS score for baseline was determined by averaging the 7 daily NRS scores directly before Day 1 (Day -7 to Day -1). The by-visit Itch NRS score for postbaseline visits was determined by averaging the 7 daily NRS scores directly before the visit day.

Time frame:
Baseline; Weeks 2 and 4
Reported as:
Number · percentage of participants
Percentage of Participants Achieving ITCH4 From Baseline to Weeks 2 and 4
percentage of participantsVehicle CreamRuxolitinib 1.5% Cream
Week 29.9 (4.4 to 18.5)47.5 (39.6 to 55.5)
Week 417.3 (9.8 to 27.3)56.3 (48.2 to 64.1)
SecondaryTime to Achieve ITCH4 During the VC Period

ITCH4 is defined as achieving a ≥4-point improvement from baseline in Itch NRS score. The Itch NRS is a once-daily patient-reported measure of itch intensity assessed using an 11-point scale (0 = no itch to 10 = worst imaginable itch) that best describes their worst level of itching in the past 24 hours. The Itch NRS score for baseline was determined by averaging the 7 daily NRS scores directly before Day 1 (Day -7 to Day -1). The by-visit Itch NRS score for postbaseline visits was determined by averaging the 7 daily NRS scores directly before the visit day.

Time frame:
up to Week 8
Reported as:
Median · days
Time to Achieve ITCH4 During the VC Period
daysVehicle CreamRuxolitinib 1.5% Cream
Time to Achieve ITCH4 During the VC Period46.0 (23.00 to NA)5.0 (4.00 to 7.00)
Statistical analysis
  • Vehicle Cream vs Ruxolitinib 1.5% Cream · Hazard ratio (hr): 2.89 · 95% CI 2.019 to 4.150estimated using a stratified Cox proportional hazard model, using Efron's method for ties.
SecondaryTime to Achieve ITCH2 During the VC Period

ITCH2 is defined as achieving a ≥2-point improvement from baseline in Itch NRS score. The Itch NRS is a once-daily patient-reported measure of itch intensity assessed using an 11-point scale (0 = no itch to 10 = worst imaginable itch) that best describes their worst level of itching in the past 24 hours. The Itch NRS score for baseline was determined by averaging the 7 daily NRS scores directly before Day 1 (Day -7 to Day -1). The by-visit Itch NRS score for postbaseline visits was determined by averaging the 7 daily NRS scores directly before the visit day.

Time frame:
up to Week 8
Reported as:
Median · days
Time to Achieve ITCH2 During the VC Period
daysVehicle CreamRuxolitinib 1.5% Cream
Time to Achieve ITCH2 During the VC Period6.0 (3.00 to 14.00)2.0 (1.00 to 2.00)
Statistical analysis
  • Vehicle Cream vs Ruxolitinib 1.5% Cream · Hazard ratio (hr): 2.10 · 95% CI 1.549 to 2.841estimated using a stratified Cox proportional hazard model, using Efron's method for ties
SecondaryChange From Baseline (Pre-application) in Current Itch NRS Score at 5, 15, 30, 45, and 60 Minutes and 2, 4, and 6 Hours Post-initial Dose on Day 1

The Itch NRS is a once-daily patient-reported measure of itch intensity assessed using an 11-point scale (0 = no itch to 10 = worst imaginable itch) that best describes their worst level of itching in the past 24 hours. The Itch NRS score for baseline was determined by averaging the 7 daily NRS scores directly before Day 1 (Day -7 to Day -1). The by-visit Itch NRS score for postbaseline visits was determined by averaging the 7 daily NRS scores directly before the visit day. Change from baseline was calculated as the post-baseline value minus the baseline value.

Time frame:
Baseline; Day 1
Reported as:
Mean · scores on a scale
Change From Baseline (Pre-application) in Current Itch NRS Score at 5, 15, 30, 45, and 60 Minutes and 2, 4, and 6 Hours Post-initial Dose on Day 1
scores on a scaleVehicle CreamRuxolitinib 1.5% Cream
Baseline7.06 ± 1.6917.13 ± 1.869
Change from baseline at 5 minutes post-initial dose-0.52 ± 1.441-0.70 ± 1.698
Change from baseline at 15 minutes post-initial dose-0.92 ± 1.622-1.54 ± 1.987
Change from baseline at 30 minutes post-initial dose-1.31 ± 1.740-2.09 ± 2.390
Change from baseline at 45 minutes post-initial dose-1.76 ± 1.946-2.35 ± 2.436
Change from baseline at 60 minutes post-initial dose-2.13 ± 2.056-2.56 ± 2.606
Change from baseline at 2 hours post-initial dose-2.13 ± 2.117-2.56 ± 2.473
Change from baseline at 4 hours post-initial dose-1.68 ± 1.918-2.67 ± 2.483
Change from baseline at 6 hours post-initial dose-1.41 ± 1.646-2.47 ± 2.390
SecondaryPercentage of Participants Achieving at Least a 2-point Decrease From Baseline in Current Itch NRS Score at 5, 15, 30, 45, and 60 Minutes and 2, 4, and 6 Hours Post-Initial Dose on Day 1

The Itch NRS is a once-daily patient-reported measure of itch intensity assessed using an 11-point scale (0 = no itch to 10 = worst imaginable itch) that best describes their worst level of itching in the past 24 hours. The Itch NRS score for baseline was determined by averaging the 7 daily NRS scores directly before Day 1 (Day -7 to Day -1). The by-visit Itch NRS score for postbaseline visits was determined by averaging the 7 daily NRS scores directly before the visit day.

Time frame:
Baseline; Day 1
Reported as:
Number · percentage of participants
Percentage of Participants Achieving at Least a 2-point Decrease From Baseline in Current Itch NRS Score at 5, 15, 30, 45, and 60 Minutes and 2, 4, and 6 Hours Post-Initial Dose on Day 1
percentage of participantsVehicle CreamRuxolitinib 1.5% Cream
5 minutes post-initial dose13.0 (6.1 to 23.3)19.7 (13.4 to 27.4)
15 minutes post-initial dose21.9 (13.1 to 33.1)35.3 (27.3 to 43.8)
30 minutes post-initial dose32.0 (21.7 to 43.8)49.3 (40.7 to 57.9)
45 minutes post-initial dose41.7 (30.2 to 53.9)55.6 (47.1 to 64.0)
60 minutes post-initial dose52.0 (40.2 to 63.7)59.2 (50.6 to 67.3)
2 hours post-initial dose46.8 (35.3 to 58.5)60.1 (51.5 to 68.4)
4 hours post-initial dose43.7 (31.9 to 56.0)59.7 (51.1 to 67.9)
6 hours post-initial dose38.6 (27.2 to 51.0)58.4 (49.2 to 67.1)
SecondaryPercentage of Participants Achieving at Least a 4-point Decrease From Baseline in Current Itch NRS Score at 5, 15, 30, 45, and 60 Minutes and 2, 4, and 6 Hours Post-Initial Dose on Day 1

The Itch NRS is a once-daily patient-reported measure of itch intensity assessed using an 11-point scale (0 = no itch to 10 = worst imaginable itch) that best describes their worst level of itching in the past 24 hours. The Itch NRS score for baseline was determined by averaging the 7 daily NRS scores directly before Day 1 (Day -7 to Day -1). The by-visit Itch NRS score for postbaseline visits was determined by averaging the 7 daily NRS scores directly before the visit day.

Time frame:
Baseline; Day 1
Reported as:
Number · percentage of participants
Percentage of Participants Achieving at Least a 4-point Decrease From Baseline in Current Itch NRS Score at 5, 15, 30, 45, and 60 Minutes and 2, 4, and 6 Hours Post-Initial Dose on Day 1
percentage of participantsVehicle CreamRuxolitinib 1.5% Cream
5 minutes post-initial dose7.6 (2.5 to 16.8)6.0 (2.6 to 11.4)
15 minutes post-initial dose7.1 (2.4 to 15.9)17.5 (11.6 to 24.9)
30 minutes post-initial dose13.9 (6.9 to 24.1)24.8 (17.8 to 32.9)
45 minutes post-initial dose20.0 (11.4 to 31.3)27.3 (20.1 to 35.5)
60 minutes post-initial dose27.8 (17.9 to 39.6)31.7 (24.0 to 40.1)
2 hours post-initial dose23.0 (14.0 to 34.2)30.1 (22.6 to 38.6)
4 hours post-initial dose14.7 (7.3 to 25.4)33.8 (25.9 to 42.4)
6 hours post-initial dose10.3 (4.2 to 20.1)29.5 (21.6 to 38.4)
SecondaryDouble-blind Treatment Period: Percentage of Participants Achieving EASI50 From Baseline at Weeks 2, 4, 8, 12, 16, 20, and 24

EASI50 was defined as achieving a ≥50% improvement in the EASI score compared to the baseline score. The EASI scoring system is a validated scoring system that grades the physical signs of atopic dermatitis (AD) to provide a measure of AD severity (ranging from 0 to 72). The disease severity strata for the EASI are: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe.

Time frame:
Baseline; Weeks 2, 4, 8, 12, 16, 20, and 24
Reported as:
Number · percentage of participants
Double-blind Treatment Period: Percentage of Participants Achieving EASI50 From Baseline at Weeks 2, 4, 8, 12, 16, 20, and 24
percentage of participantsVehicle CreamRuxolitinib 1.5% Cream
Week 211.1 (5.2 to 20.0)69.4 (61.6 to 76.4)
Week 425.9 (16.8 to 36.9)79.4 (72.3 to 85.4)
Week 824.7 (15.8 to 35.5)80.6 (73.6 to 86.4)
Week 12100.0 (81.5 to 100.0)89.1 (82.0 to 94.1)
Week 16100.0 (76.8 to 100.0)94.6 (88.6 to 98.0)
Week 2092.9 (66.1 to 99.8)94.3 (88.0 to 97.9)
Week 24100.0 (75.3 to 100.0)96.1 (90.4 to 98.9)
Statistical analysis
  • Vehicle Cream vs Ruxolitinib 1.5% Cream · Odds ratio (or): 13.41 · 95% CI 6.963 to 25.816stratified by baseline EASI score and geographic region
SecondaryDouble-blind Treatment Period: Percentage of Participants With EASI90 From Baseline at Weeks 2, 4, 8, 12, 16, 20, and 24

EASI90 was defined as achieving a ≥90% improvement in the EASI score compared to the baseline score. The EASI scoring system is a validated scoring system that grades the physical signs of atopic dermatitis (AD) to provide a measure of AD severity (ranging from 0 to 72). The disease severity strata for the EASI are: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe.

Time frame:
Baseline; Weeks 2, 4, 8, 12, 16, 20, and 24
Reported as:
Number · percentage of participants
Double-blind Treatment Period: Percentage of Participants With EASI90 From Baseline at Weeks 2, 4, 8, 12, 16, 20, and 24
percentage of participantsVehicle CreamRuxolitinib 1.5% Cream
Week 21.2 (0.0 to 6.7)21.9 (15.7 to 29.1)
Week 44.9 (1.4 to 12.2)41.3 (33.5 to 49.3)
Week 88.6 (3.5 to 17.0)56.9 (48.8 to 64.7)
Week 1250.0 (26.0 to 74.0)53.8 (44.4 to 63.0)
Week 1657.1 (28.9 to 82.3)64.0 (54.3 to 72.9)
Week 2057.1 (28.9 to 82.3)57.1 (47.1 to 66.8)
Week 2446.2 (19.2 to 74.9)66.0 (56.0 to 75.1)
Statistical analysis
  • Vehicle Cream vs Ruxolitinib 1.5% Cream · Odds ratio (or): 14.39 · 95% CI 6.099 to 33.952stratified by baseline EASI score and geographic region
SecondaryDouble-blind Treatment Period: Percentage of Participants Achieving Both EASI75 and IGA-TS at Weeks 2, 4, 8, 12, 16, 20, and 24

EASI75=a ≥75% improvement in the EASI score compared to the baseline score. The EASI scoring system grades the physical signs of AD to provide a measure of severity (range=0-72). EASI disease severity strata: 0 = clear; 0.1-1.0 = almost clear; 1.1-7.0 = mild; 7.1-21.0 = moderate; 21.1-50.0 = severe; 50.1 to 72.0 = very severe. IGA-TS = an IGA score of 0 or 1 with a ≥2-grade improvement from baseline. The IGA is an overall eczema severity rating on a 0 to 4 scale. 0: clear; no erythema or induration/papulation, no oozing/crusting; there may be minor residual discoloration. 1: almost clear; may be trace faint pink erythema, with almost no induration/papulation, and no oozing/crusting. 2: mild; may be faint pink erythema, with mild induration/papulation and no oozing/crusting. 3: moderate; may be pink-red erythema with moderate induration/papulation and may be some oozing/crusting. 4: severe; may be deep or bright red erythema with severe induration/papulation and with oozing/crusting.

Time frame:
Baseline; Weeks 2, 4, 8, 12, 16, 20, and 24
Reported as:
Number · percentage of participants
Double-blind Treatment Period: Percentage of Participants Achieving Both EASI75 and IGA-TS at Weeks 2, 4, 8, 12, 16, 20, and 24
percentage of participantsVehicle CreamRuxolitinib 1.5% Cream
Week 22.5 (0.3 to 8.6)26.3 (19.6 to 33.8)
Week 49.9 (4.4 to 18.5)46.3 (38.3 to 54.3)
Week 813.6 (7.0 to 23.0)59.4 (51.3 to 67.1)
Week 1261.1 (35.7 to 82.7)63.0 (53.7 to 71.7)
Week 1671.4 (41.9 to 91.6)63.1 (53.4 to 72.0)
Week 2064.3 (35.1 to 87.2)66.7 (56.8 to 75.6)
Week 2469.2 (38.6 to 90.9)69.9 (60.1 to 78.5)
Statistical analysis
  • Vehicle Cream vs Ruxolitinib 1.5% Cream · Odds ratio (or): 9.33 · 95% CI 4.532 to 19.207stratified by baseline EASI score and geographic region
SecondaryChange From Baseline for Atopic Dermatitis-affected %Body Surface Area (BSA) at Weeks 2, 4, and 8 of the Double-blind Treatment Period

BSA assessment was approximated to the nearest 0.1% using the handprint (Palmar) method as a guide. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits, with fingers tucked together and thumb tucked to the side) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Change from baseline was calculated as the post-baseline value minus the baseline value.

Time frame:
Baseline; Weeks 2, 4, and 8
Reported as:
Least squares mean · percentage of BSA
Change From Baseline for Atopic Dermatitis-affected %Body Surface Area (BSA) at Weeks 2, 4, and 8 of the Double-blind Treatment Period
percentage of BSAVehicle CreamRuxolitinib 1.5% Cream
Change from baseline at Week 2-1.04 ± 0.622-6.96 ± 0.417
Change from baseline at Week 4-2.36 ± 0.683-9.30 ± 0.455
Change from baseline at Week 8-4.22 ± 0.671-10.84 ± 0.435
Statistical analysis
  • Vehicle Cream vs Ruxolitinib 1.5% Cream · Lsm difference: -5.92 · 95% CI -7.40 to -4.44
  • Vehicle Cream vs Ruxolitinib 1.5% Cream · Lsm difference: -6.94 · 95% CI -8.56 to -5.32
  • Vehicle Cream vs Ruxolitinib 1.5% Cream · Lsm difference: -6.62 · 95% CI -8.19 to -5.04
SecondaryChange From Baseline for Atopic Dermatitis-affected %BSA at Weeks 12, 16, 20, and 24 of the Double-blind Treatment Period

BSA assessment was approximated to the nearest 0.1% using the handprint (Palmar) method as a guide. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits, with fingers tucked together and thumb tucked to the side) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Change from baseline was calculated as the post-baseline value minus the baseline value.

Time frame:
Baseline; Weeks 12, 16, 20, and 24
Reported as:
Mean · percentage of BSA
Change From Baseline for Atopic Dermatitis-affected %BSA at Weeks 12, 16, 20, and 24 of the Double-blind Treatment Period
percentage of BSAVehicle CreamRuxolitinib 1.5% Cream
Baseline15.43 ± 2.94714.98 ± 3.068
Change from baseline at Week 12-11.28 ± 3.230-11.79 ± 4.725
Change from baseline at Week 16-11.74 ± 4.010-12.22 ± 4.109
Change from baseline at Week 20-11.26 ± 4.309-12.04 ± 4.559
Change from baseline at Week 24-11.83 ± 3.255-12.50 ± 4.691
SecondaryChange From Baseline for the EASI Score at Weeks 2, 4, and 8 of the Double-blind Treatment Period

The EASI scoring system is a validated scoring system that grades the physical signs of atopic dermatitis (AD) to provide a measure of AD severity (ranging from 0 to 72). The disease severity strata for the EASI are: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. Change from baseline was calculated as the post-baseline value minus the baseline value.

Time frame:
Baseline; Weeks 2, 4, and 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline for the EASI Score at Weeks 2, 4, and 8 of the Double-blind Treatment Period
scores on a scaleVehicle CreamRuxolitinib 1.5% Cream
Change from baseline at Week 2-1.50 ± 0.509-7.59 ± 0.341
Change from baseline at Week 4-3.14 ± 0.509-9.24 ± 0.340
Change from baseline at Week 8-4.49 ± 0.508-9.80 ± 0.330
Statistical analysis
  • Vehicle Cream vs Ruxolitinib 1.5% Cream · Lsm difference: -6.09 · 95% CI -7.30 to -4.88
  • Vehicle Cream vs Ruxolitinib 1.5% Cream · Lsm difference: -6.10 · 95% CI -7.30 to -4.89
  • Vehicle Cream vs Ruxolitinib 1.5% Cream · Lsm difference: -5.31 · 95% CI -6.51 to -4.12
SecondaryChange From Baseline for the EASI Score at Weeks 12, 16, 20, and 24 of the Double-blind Treatment Period

The EASI scoring system is a validated scoring system that grades the physical signs of atopic dermatitis (AD) to provide a measure of AD severity (ranging from 0 to 72). The disease severity strata for the EASI are: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. Change from baseline was calculated as the post-baseline value minus the baseline value.

Time frame:
Baseline; Weeks 12, 16, 20, and 24
Reported as:
Mean · scores on a scale
Change From Baseline for the EASI Score at Weeks 12, 16, 20, and 24 of the Double-blind Treatment Period
scores on a scaleVehicle CreamRuxolitinib 1.5% Cream
Baseline12.84 ± 3.63412.50 ± 4.280
Change from baseline at Week 12-10.33 ± 3.999-10.17 ± 4.575
Change from baseline at Week 16-9.38 ± 2.580-10.79 ± 4.176
Change from baseline at Week 20-9.12 ± 3.120-10.86 ± 3.861
Change from baseline at Week 24-9.63 ± 2.700-10.93 ± 4.020
SecondaryChange From Baseline for the SCORing Atopic Dermatitis (SCORAD) Score at Weeks 2, 4, and 8 of the Double-blind Treatment Period

The SCORAD assesses the extent and severity (intensity) of eczema. To determine extent, the rule of 9 or handprint method was used to calculate the eczema affected area (A) as a percentage of the whole body. Scores were added to give a possible maximum of 100%. To determine intensity, a representative area of eczema was selected. The intensity of redness, swelling, oozing/crusting, scratch marks, skin thickening (lichenification), dryness was assessed individually: none, 0; mild, 1; moderate, 2; severe, 3. Intensity scores were added together to give "B" (maximum score of 18). Subjective symptoms (itch and sleeplessness) were scored by the participant using a visual analog scale on which "0" was no itch (or no sleeplessness) and "10" was the worst imaginable itch (or sleeplessness). These scores were added to give "C" (maximum score of 20). The total score\[KM25.1\] (ranging from 0 to 103; a higher score indicates greater extent and severity) was calculated as: A/5 + 7B/2 + C.

Time frame:
Baseline; Weeks 2, 4, and 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline for the SCORing Atopic Dermatitis (SCORAD) Score at Weeks 2, 4, and 8 of the Double-blind Treatment Period
scores on a scaleVehicle CreamRuxolitinib 1.5% Cream
Change from baseline at Week 2-6.12 ± 1.662-26.08 ± 1.115
Change from baseline at Week 4-11.28 ± 1.769-32.68 ± 1.181
Change from baseline at Week 8-14.71 ± 1.942-35.79 ± 1.262
Statistical analysis
  • Vehicle Cream vs Ruxolitinib 1.5% Cream · Lsm difference: -19.96 · 95% CI -23.91 to -16.02
  • Vehicle Cream vs Ruxolitinib 1.5% Cream · Lsm difference: -21.40 · 95% CI -25.59 to -17.21
  • Vehicle Cream vs Ruxolitinib 1.5% Cream · Lsm difference: -21.08 · 95% CI -25.65 to -16.52
SecondaryChange From Baseline for the SCORAD Score at Weeks 12, 16, 20, and 24 of the Double-blind Treatment Period

The SCORAD assesses the extent and severity (intensity) of eczema. To determine extent, the rule of 9 or handprint method was used to calculate the eczema affected area (A) as a percentage of the whole body. Scores were added to give a possible maximum of 100%. To determine intensity, a representative area of eczema was selected. The intensity of redness, swelling, oozing/crusting, scratch marks, skin thickening (lichenification), dryness was assessed individually: none, 0; mild, 1; moderate, 2; severe, 3. Intensity scores were added together to give "B" (maximum score of 18). Subjective symptoms (itch and sleeplessness) were scored by the participant using a visual analog scale on which "0" was no itch (or no sleeplessness) and "10" was the worst imaginable itch (or sleeplessness). These scores were added to give "C" (maximum score of 20). The total score\[KM27.1\] (ranging from 0 to 103; a higher score indicates greater extent and severity) was calculated as: A/5 + 7B/2 + C.

Time frame:
Baseline; Weeks 12, 16, 20, and 24
Reported as:
Mean · scores on a scale
Change From Baseline for the SCORAD Score at Weeks 12, 16, 20, and 24 of the Double-blind Treatment Period
scores on a scaleVehicle CreamRuxolitinib 1.5% Cream
Baseline53.11 ± 10.42953.90 ± 10.938
Change from baseline at Week 12-29.80 ± 13.377-36.32 ± 14.801
Change from baseline at Week 16-33.36 ± 14.448-38.14 ± 15.264
Change from baseline at Week 20-32.29 ± 15.272-39.53 ± 14.092
Change from baseline at Week 24-35.41 ± 12.494-39.08 ± 13.714
SecondaryChange From Baseline for Itch NRS Score at Days 1 Through 56 (8 Weeks)

The Itch NRS is a once-daily patient-reported measure of itch intensity assessed using an 11-point scale (0 = no itch to 10 = worst imaginable itch) that best describes their worst level of itching in the past 24 hours. The Itch NRS score for baseline was determined by averaging the 7 daily NRS scores directly before Day 1 (Day -7 to Day -1). The by-visit Itch NRS score for postbaseline visits was determined by averaging the 7 daily NRS scores directly before the visit day. Change from baseline was calculated as the post-baseline value minus the baseline value.

Time frame:
Baseline; Days 1 through 56 (8 weeks)
Reported as:
Least squares mean · scores on a scale
Change From Baseline for Itch NRS Score at Days 1 Through 56 (8 Weeks)
scores on a scaleVehicle CreamRuxolitinib 1.5% Cream
Change from baseline at Day 1-1.03 ± 0.244-1.80 ± 0.175
Change from baseline at Day 2-0.99 ± 0.260-2.65 ± 0.186
Change from baseline at Day 3-1.13 ± 0.263-2.97 ± 0.190
Change from baseline at Day 4-1.18 ± 0.276-3.38 ± 0.191
Change from baseline at Day 5-0.99 ± 0.272-3.52 ± 0.196
Change from baseline at Day 6-0.94 ± 0.294-3.68 ± 0.208
Change from baseline at Day 7-1.06 ± 0.275-3.77 ± 0.201
Change from baseline at Day 8-1.15 ± 0.310-3.83 ± 0.212
Change from baseline at Day 9-1.27 ± 0.307-3.90 ± 0.212
Change from baseline at Day 10-1.22 ± 0.296-3.89 ± 0.215
Change from baseline at Day 11-1.40 ± 0.324-4.18 ± 0.223
Change from baseline at Day 12-1.27 ± 0.314-4.19 ± 0.222
Change from baseline at Day 13-1.60 ± 0.333-4.33 ± 0.224
Change from baseline at Day 14-1.40 ± 0.316-4.33 ± 0.217
Change from baseline at Day 15-1.56 ± 0.329-4.47 ± 0.220
Change from baseline at Day 16-1.59 ± 0.336-4.60 ± 0.222
Change from baseline at Day 17-2.02 ± 0.339-4.52 ± 0.225
Change from baseline at Day 18-1.87 ± 0.334-4.83 ± 0.221
Change from baseline at Day 19-1.60 ± 0.321-4.65 ± 0.217
Change from baseline at Day 20-1.92 ± 0.325-4.79 ± 0.216
Change from baseline at Day 21-1.79 ± 0.325-4.68 ± 0.212
Change from baseline at Day 22-1.89 ± 0.328-4.69 ± 0.218
Change from baseline at Day 23-1.80 ± 0.350-4.62 ± 0.231
Change from baseline at Day 24-2.00 ± 0.335-4.70 ± 0.218
Change from baseline at Day 25-2.05 ± 0.358-4.78 ± 0.235
Change from baseline at Day 26-2.05 ± 0.363-4.70 ± 0.237
Change from baseline at Day 27-1.91 ± 0.352-4.74 ± 0.233
Change from baseline at Day 28-2.05 ± 0.350-4.91 ± 0.229
Change from baseline at Day 29-2.15 ± 0.361-4.93 ± 0.231
Change from baseline at Day 30-2.34 ± 0.347-5.03 ± 0.225
Change from baseline at Day 31-2.19 ± 0.347-4.99 ± 0.236
Change from baseline at Day 32-2.32 ± 0.339-4.98 ± 0.229
Change from baseline at Day 33-2.29 ± 0.370-5.10 ± 0.240
Change from baseline at Day 34-2.54 ± 0.339-5.16 ± 0.233
Change from baseline at Day 35-2.69 ± 0.389-4.90 ± 0.233
Change from baseline at Day 36-2.56 ± 0.371-5.16 ± 0.245
Change from baseline at Day 37-2.72 ± 0.379-4.99 ± 0.239
Change from baseline at Day 38-2.39 ± 0.359-4.87 ± 0.234
Change from baseline at Day 39-2.33 ± 0.359-4.99 ± 0.241
Change from baseline at Day 40-2.16 ± 0.392-4.99 ± 0.237
Change from baseline at Day 41-2.66 ± 0.395-5.03 ± 0.249
Change from baseline at Day 42-2.34 ± 0.349-5.20 ± 0.226
Change from baseline at Day 43-2.79 ± 0.373-5.23 ± 0.237
Change from baseline at Day 44-2.84 ± 0.390-5.22 ± 0.236
Change from baseline at Day 45-2.63 ± 0.351-5.17 ± 0.246
Change from baseline at Day 46-2.60 ± 0.375-5.18 ± 0.242
Change from baseline at Day 47-2.69 ± 0.373-5.26 ± 0.235
Change from baseline at Day 48-2.38 ± 0.364-5.27 ± 0.229
Change from baseline at Day 49-2.38 ± 0.379-5.17 ± 0.250
Change from baseline at Day 50-2.63 ± 0.362-5.07 ± 0.235
Change from baseline at Day 51-2.51 ± 0.424-5.05 ± 0.262
Change from baseline at Day 52-2.27 ± 0.421-5.18 ± 0.248
Change from baseline at Day 53-2.53 ± 0.385-5.28 ± 0.251
Change from baseline at Day 54-2.89 ± 0.421-5.14 ± 0.250
Change from baseline at Day 55-2.93 ± 0.426-5.26 ± 0.266
Change from baseline at Day 56-2.84 ± 0.456-4.96 ± 0.284
SecondaryChange From Baseline for Skin Pain NRS Score at Weeks 2, 4, and 8 of the Double-blind Treatment Period

The Skin Pain NRS is a daily participant-reported measure (24-hour or 7-day recall) of the worst level of pain intensity from 0 (no pain) to 10 (worst pain imaginable). Participants were asked to rate the pain intensity by selecting a number that best describes the worst level of pain in the past 24 hours during the VC period and in the past 7 days during the VCE period. Change from baseline was calculated as the post-baseline value minus the baseline value.

Time frame:
Baseline; Weeks 2, 4, and 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline for Skin Pain NRS Score at Weeks 2, 4, and 8 of the Double-blind Treatment Period
scores on a scaleVehicle CreamRuxolitinib 1.5% Cream
Change from baseline at Week 2-1.60 ± 0.278-4.20 ± 0.185
Change from baseline at Week 4-2.08 ± 0.280-4.79 ± 0.186
Change from baseline at Week 8-2.62 ± 0.304-5.12 ± 0.197
Statistical analysis
  • Vehicle Cream vs Ruxolitinib 1.5% Cream · Lsm difference: -2.60 · 95% CI -3.26 to -1.94
  • Vehicle Cream vs Ruxolitinib 1.5% Cream · Lsm difference: -2.71 · 95% CI -3.37 to -2.05
  • Vehicle Cream vs Ruxolitinib 1.5% Cream · Lsm difference: -2.49 · 95% CI -3.21 to -1.78
SecondarySkin Pain NRS Score at Weeks 12, 16, 20, and 24 of the Double-blind Treatment Period

The Skin Pain NRS is a daily participant-reported measure (24-hour or 7-day recall) of the worst level of pain intensity from 0 (no pain) to 10 (worst pain imaginable). Participants were asked to rate the pain intensity by selecting a number that best describes the worst level of pain in the past 24 hours during the VC period and in the past 7 days during the VCE period.

Time frame:
Baseline; Weeks 12, 16, 20, and 24
Reported as:
Mean · scores on a scale
Skin Pain NRS Score at Weeks 12, 16, 20, and 24 of the Double-blind Treatment Period
scores on a scaleVehicle CreamRuxolitinib 1.5% Cream
Week 123.17 ± 2.8341.97 ± 2.214
Week 162.00 ± 2.6022.03 ± 2.192
Week 202.43 ± 2.4411.58 ± 1.788
Week 242.62 ± 2.0221.62 ± 1.990
SecondaryTime to Open-label Escape Arm

The study allowed participants to move to an open-label ruxolitinib 1.5% escape arm if they had not met EASI50 (50% improvement in the EASI score from baseline at 2 consecutive visits at least 1 week apart) at Week 8 (end of the double-blind, vehicle-controlled period and the start of the vehicle-controlled extension, double-blind period) or if they lost EASI50 response during the vehicle-controlled extension, double-blind period. Participants who were moved to the open-label ruxolitinib 1.5% escape arm without meeting the criteria were censored.

Time frame:
up to 16 weeks (from Week 8 to Week 24)
Reported as:
Median · days
Time to Open-label Escape Arm
daysVehicle CreamRuxolitinib 1.5% Cream
Time to Open-label Escape Arm1.0 (NA to NA)NA (NA to NA)
Statistical analysis
  • Vehicle Cream vs Ruxolitinib 1.5% Cream · Hazard ratio (hr): 0.18 · 95% CI 0.113 to 0.304Hazard ratio between the two groups was estimated using a stratified Cox proportional hazard model, using Efron's method for ties.
SecondaryPercentage of Participants in the VCE DB Period Concurrently Meeting All of the Following Criteria: IGA Score ≥3, EASI Score ≥16, Itch NRS Score, ≥4, BSA ≥10%, and Dermatology Life Quality Index (DLQI) Score >10

Only data in the DB treatment period were included in the analysis.

Time frame:
up to 16 weeks (from Week 8 to Week 24)
Reported as:
Number · percentage of participants
Percentage of Participants in the VCE DB Period Concurrently Meeting All of the Following Criteria: IGA Score ≥3, EASI Score ≥16, Itch NRS Score, ≥4, BSA ≥10%, and Dermatology Life Quality Index (DLQI) Score >10
percentage of participantsVehicle CreamRuxolitinib 1.5% Cream
Percentage of Participants in the VCE DB Period Concurrently Meeting All of the Following Criteria: IGA Score ≥3, EASI Score ≥16, Itch NRS Score, ≥4, BSA ≥10%, and Dermatology Life Quality Index (DLQI) Score >1014.83.8
SecondaryTime to Participants in the VCE DB Period Concurrently Meeting All of the Following Criteria: IGA Score ≥3, EASI Score ≥16, Itch NRS Score ≥4, BSA ≥10%, and DLQI Score >10

Only data in the DB treatment period were included in the analysis.

Time frame:
up to 16 weeks (from Week 8 to Week 24)
Reported as:
Median · days
Time to Participants in the VCE DB Period Concurrently Meeting All of the Following Criteria: IGA Score ≥3, EASI Score ≥16, Itch NRS Score ≥4, BSA ≥10%, and DLQI Score >10
daysVehicle CreamRuxolitinib 1.5% Cream
Time to Participants in the VCE DB Period Concurrently Meeting All of the Following Criteria: IGA Score ≥3, EASI Score ≥16, Itch NRS Score ≥4, BSA ≥10%, and DLQI Score >10NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Vehicle Cream vs Ruxolitinib 1.5% Cream · Hazard ratio (hr): 0.13 · 95% CI 0.045 to 0.395
SecondaryPercentage of Participants Who Experienced a Relapse After Study Treatment Discontinuation

Relapse was assessed during the 30-day Safety Follow-up Period for participants who had an EASI75 response from baseline at the end of the VCE DB period at Week 24. Participants who experienced a relapse were those among EASI75 responders who were on study treatment at Week 24 who met relapse criteria (loss of EASI50 from baseline) at the safety follow-up visit.

Time frame:
up to 30 days following Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced a Relapse After Study Treatment Discontinuation
percentage of participantsVehicle CreamRuxolitinib 1.5% Cream
Percentage of Participants Who Experienced a Relapse After Study Treatment Discontinuation0.0018.52
SecondaryTime to First Retreatment During the VCE DB Period

Time to first retreatment following the participant's first lesion clearance during the VCE DB period was evaluated in participants who had at least 1 occurrence of lesion clearance.

Time frame:
up to 16 weeks (from Week 8 to Week 24)
Reported as:
Median · days
Time to First Retreatment During the VCE DB Period
daysVehicle CreamRuxolitinib 1.5% Cream
Time to First Retreatment During the VCE DB Period26.0 (2.00 to NA)5.0 (4.00 to 6.00)
SecondaryPercentage of Time Off Study Treatment Due to Lesion Clearance During the VCE DB Period

The percentage of time off study treatment was calculated as the total days off study treatment due to lesion clearance divided by the total days between two visits per participant.

Time frame:
from Week 8 to Week 12; from Week 12 to Week 16; from Week 16 to Week 20; from Week 20 to Week 24
Reported as:
Mean · percentage of days
Percentage of Time Off Study Treatment Due to Lesion Clearance During the VCE DB Period
percentage of daysVehicle CreamRuxolitinib 1.5% Cream
Week 8 to Week 124.10 ± 14.04115.83 ± 23.644
Week 12 to Week 1619.16 ± 38.27517.86 ± 27.221
Week 16 to Week 2021.86 ± 41.70722.72 ± 30.994
Week 20 to Week 2426.12 ± 38.32324.29 ± 32.962
SecondaryPercentage of Time on Study Treatment During the VCE DB Period

The percentage of time on study treatment was calculated as the total days intended on study treatment divided by the total days between two visits per participant.

Time frame:
from Week 8 to Week 12; from Week 12 to Week 16; from Week 16 to Week 20; from Week 20 to Week 24
Reported as:
Mean · percentage of days
Percentage of Time on Study Treatment During the VCE DB Period
percentage of daysVehicle CreamRuxolitinib 1.5% Cream
Week 8 to Week 1290.97 ± 18.72979.28 ± 26.663
Week 12 to Week 1679.83 ± 37.79776.43 ± 29.169
Week 16 to Week 2076.63 ± 41.36272.46 ± 31.409
Week 20 to Week 2472.70 ± 38.90571.25 ± 33.319
SecondaryDouble-blind Treatment Period: Percentage of Participants Who Achieved a ≥4-point Improvement in Dermatology Life Quality Index (DLQI) From Baseline at Weeks 2, 4, 8, 12, 16, 20, and 24

The DLQI is 10-question validated questionnaire measuring how much the skin problem has affected the participant over the previous 7 days. The questionnaire is analyzed under 6 headings: symptoms and feelings (Questions 1 and 2); daily activities (Questions 3 and 4); leisure (Questions 5 and 6); work and school (Question 7); personal relations (Questions 8 and 9); treatment (Question 10). The scoring of each question is: 3, very much; 2, a lot; 1, a little; 0, not at all; not relevant, 0; Question 7, "prevented work or studying," 3. The DLQI is calculated by summing the scores of each question, resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired. Total DLQI scores can be categorized as: 0-1, no effect; 2-5, small effect; 6-10, moderate effect; 11-20, very large effect; 21-30, extremely large effect.

Time frame:
Baseline; Weeks 2, 4, 12, 16, 20, and 24
Reported as:
Number · percentage of participants
Double-blind Treatment Period: Percentage of Participants Who Achieved a ≥4-point Improvement in Dermatology Life Quality Index (DLQI) From Baseline at Weeks 2, 4, 8, 12, 16, 20, and 24
percentage of participantsVehicle CreamRuxolitinib 1.5% Cream
Week 267.1 (54.9 to 77.9)93.1 (88.0 to 96.5)
Week 470.6 (58.3 to 81.0)94.8 (90.0 to 97.7)
Week 877.6 (64.7 to 87.5)97.4 (93.4 to 99.3)
Week 1288.9 (65.3 to 98.6)97.4 (92.6 to 99.5)
Week 16100.0 (76.8 to 100.0)96.4 (91.0 to 99.0)
Week 20100.0 (76.8 to 100.0)99.0 (94.8 to 100.0)
Week 2484.6 (54.6 to 98.1)99.0 (94.7 to 100.0)
Statistical analysis
  • Vehicle Cream vs Ruxolitinib 1.5% Cream · Response rate difference: 19.76 · 95% CI 8.731 to 30.798The confidence interval was calculated based on Wald method without continuity correction.
SecondaryChange From Baseline in the DLQI Score at Weeks 2, 4, and 8 of the Double-blind Treatment Period

The DLQI is 10-question validated questionnaire measuring how much the skin problem has affected the participant over the previous 7 days. The questionnaire is analyzed under 6 headings: symptoms and feelings (Questions 1 and 2); daily activities (Questions 3 and 4); leisure (Questions 5 and 6); work and school (Question 7); personal relations (Questions 8 and 9); treatment (Question 10). The scoring of each question is: 3, very much; 2, a lot; 1, a little; 0, not at all; not relevant, 0; Question 7, "prevented work or studying," 3. The DLQI is calculated by summing the scores of each question, resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired. Total DLQI scores can be categorized as: 0-1, no effect; 2-5, small effect; 6-10, moderate effect; 11-20, very large effect; 21-30, extremely large effect. Change from baseline was calculated as the post-baseline value minus the baseline value.

Time frame:
Baseline; Weeks 2, 4, and 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline in the DLQI Score at Weeks 2, 4, and 8 of the Double-blind Treatment Period
scores on a scaleVehicle CreamRuxolitinib 1.5% Cream
Change from baseline at Week 2-5.79 ± 0.709-12.66 ± 0.472
Change from baseline at Week 4-7.67 ± 0.716-14.20 ± 0.478
Change from baseline at Week 8-8.33 ± 0.692-15.13 ± 0.445
Statistical analysis
  • Vehicle Cream vs Ruxolitinib 1.5% Cream · Lsm difference: -6.87 · 95% CI -8.55 to -5.20
  • Vehicle Cream vs Ruxolitinib 1.5% Cream · Lsm difference: -6.53 · 95% CI -8.22 to -4.83
  • Vehicle Cream vs Ruxolitinib 1.5% Cream · Lsm difference: -6.80 · 95% CI -8.42 to -5.18
SecondaryChange From Baseline in the DLQI Score at Weeks 12, 16, 20, and 24 of the Double-blind Treatment Period

The DLQI is 10-question validated questionnaire measuring how much the skin problem has affected the participant over the previous 7 days. The questionnaire is analyzed under 6 headings: symptoms and feelings (Questions 1 and 2); daily activities (Questions 3 and 4); leisure (Questions 5 and 6); work and school (Question 7); personal relations (Questions 8 and 9); treatment (Question 10). The scoring of each question is: 3, very much; 2, a lot; 1, a little; 0, not at all; not relevant, 0; Question 7, "prevented work or studying," 3. The DLQI is calculated by summing the scores of each question, resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired. Total DLQI scores can be categorized as: 0-1, no effect; 2-5, small effect; 6-10, moderate effect; 11-20, very large effect; 21-30, extremely large effect. Change from baseline was calculated as the post-baseline value minus the baseline value.

Time frame:
Baseline; Weeks 12, 16, 20, and 24
Reported as:
Mean · scores on a scale
Change From Baseline in the DLQI Score at Weeks 12, 16, 20, and 24 of the Double-blind Treatment Period
scores on a scaleVehicle CreamRuxolitinib 1.5% Cream
Baseline19.10 ± 5.17619.31 ± 5.057
Change from baseline at Week 12-14.11 ± 8.331-15.51 ± 6.307
Change from baseline at Week 16-16.79 ± 7.138-15.95 ± 6.406
Change from baseline at Week 20-16.43 ± 7.398-16.59 ± 5.988
Change from baseline at Week 24-16.00 ± 8.963-16.28 ± 6.069
SecondaryChange From Baseline in the Patient-oriented Eczema Measure (POEM) Score at Weeks 2, 4, and 8 of the Double-blind Treatment Period

The POEM is a 7-question quality-of-life assessment used for monitoring atopic eczema severity, focusing on the illness as experienced by the participant. The questionnaire asks how many days the participant has been bothered by various aspects of their skin condition during the past week. The response options and corresponding scoring questionnaires are: no days (0), 1 to 2 days (1), 3 to 4 days (2), 5 to 6 days (3), and every day (4), with total scores ranging from 0 to 28. The meaning of POEM scores can be categorized as: 0 to 2 (clear/almost clear), 3 to 7 (mild eczema), 8 to 16 (moderate eczema), 17 to 24 (severe eczema), and 25 to 28 (very severe eczema). Change from baseline was calculated as the post-baseline value minus the baseline value.

Time frame:
Baseline; Weeks 2, 4, and 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline in the Patient-oriented Eczema Measure (POEM) Score at Weeks 2, 4, and 8 of the Double-blind Treatment Period
scores on a scaleVehicle CreamRuxolitinib 1.5% Cream
Change from baseline at Week 2-4.48 ± 0.768-12.61 ± 0.517
Change from baseline at Week 4-5.54 ± 0.748-14.22 ± 0.504
Change from baseline at Week 8-6.62 ± 0.834-14.71 ± 0.543
Statistical analysis
  • Vehicle Cream vs Ruxolitinib 1.5% Cream · Lsm difference: -8.12 · 95% CI -9.95 to -6.30
  • Vehicle Cream vs Ruxolitinib 1.5% Cream · Lsm difference: -8.68 · 95% CI -10.46 to -6.90
  • Vehicle Cream vs Ruxolitinib 1.5% Cream · Lsm difference: -8.09 · 95% CI -10.05 to -6.12
SecondaryChange From Baseline in the POEM Score at Weeks 12, 16, 20, and 24 of the Double-blind Treatment Period

The POEM is a 7-question quality-of-life assessment used for monitoring atopic eczema severity, focusing on the illness as experienced by the participant. The questionnaire asks how many days the participant has been bothered by various aspects of their skin condition during the past week. The response options and corresponding scoring questionnaires are: no days (0), 1 to 2 days (1), 3 to 4 days (2), 5 to 6 days (3), and every day (4), with a range in total score of 0 to 28. The meaning of POEM scores can be categorized as: 0 to 2 (clear/almost clear), 3 to 7 (mild eczema), 8 to 16 (moderate eczema), 17 to 24 (severe eczema), and 25 to 28 (very severe eczema). Change from baseline was calculated as the post-baseline value minus the baseline value.

Time frame:
Baseline; Weeks 12, 16, 20, and 24
Reported as:
Mean · scores on a scale
Change From Baseline in the POEM Score at Weeks 12, 16, 20, and 24 of the Double-blind Treatment Period
scores on a scaleVehicle CreamRuxolitinib 1.5% Cream
Baseline19.61 ± 5.30720.53 ± 4.903
Change from baseline at Week 12-12.11 ± 7.340-14.54 ± 6.761
Change from baseline at Week 16-13.00 ± 7.401-14.57 ± 6.947
Change from baseline at Week 20-11.71 ± 8.888-14.51 ± 7.115
Change from baseline at Week 24-12.23 ± 10.553-14.86 ± 7.208
SecondaryChange From Baseline in the EQ-5D-5L Visual Analog Scale Score at Weeks 2, 4, and 8 of the Double-blind Treatment Period

The EQ-5D is a validated, self-administered, generic utility questionnaire wherein participants rate their current health state based on the following criteria (dimensions): mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The 5L indicates that, for each dimension, there are 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The participant was asked to indicate his/her health state over the past 7 days using a scale ranging from 0 (worst imaginable health) to 100 (best imaginable health). Missing values were not imputed. Change from Baseline was calculated as the post-baseline value minus the baseline value.

Time frame:
Baseline; Weeks 2, 4, and 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline in the EQ-5D-5L Visual Analog Scale Score at Weeks 2, 4, and 8 of the Double-blind Treatment Period
scores on a scaleVehicle CreamRuxolitinib 1.5% Cream
Change from baseline at Week 25.65 ± 1.58912.34 ± 1.066
Change from baseline at Week 45.84 ± 1.82214.38 ± 1.227
Change from baseline at Week 84.37 ± 1.76116.48 ± 1.124
Statistical analysis
  • Vehicle Cream vs Ruxolitinib 1.5% Cream · Lsm difference: 6.69 · 95% CI 2.91 to 10.46
  • Vehicle Cream vs Ruxolitinib 1.5% Cream · Lsm difference: 8.54 · 95% CI 4.21 to 12.88
  • Vehicle Cream vs Ruxolitinib 1.5% Cream · Lsm difference: 12.11 · 95% CI 7.99 to 16.24
SecondaryChange From Baseline in the EQ-5D-5L Visual Analog Scale Score at Weeks 12, 16, 20, and 24 of the Double-blind Treatment Period

The EQ-5D is a validated, self-administered, generic utility questionnaire wherein participants rate their current health state based on the following criteria (dimensions): mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The 5L indicates that, for each dimension, there are 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The participant was asked to indicate his/her health state over the past 7 days using a scale ranging from 0 (worst imaginable health) to 100 (best imaginable health). Missing values were not imputed. Change from Baseline was calculated as the post-baseline value minus the baseline value.

Time frame:
Baseline; Weeks 12, 16, 20, and 24
Reported as:
Mean · scores on a scale
Change From Baseline in the EQ-5D-5L Visual Analog Scale Score at Weeks 12, 16, 20, and 24 of the Double-blind Treatment Period
scores on a scaleVehicle CreamRuxolitinib 1.5% Cream
Baseline71.09 ± 18.74266.26 ± 20.738
Change from baseline at Week 125.50 ± 16.16916.93 ± 23.868
Change from baseline at Week 169.71 ± 16.22619.41 ± 21.764
Change from baseline at Week 209.14 ± 15.16019.94 ± 21.208
Change from baseline at Week 2410.69 ± 10.69620.69 ± 20.777
SecondaryChange From Baseline in the Hospital Anxiety and Depression Scale (HADS) Score at Weeks 2, 4, and 8 of the Double-blind Treatment Period

The HADS is a 14-item questionnaire that assesses the levels of anxiety and depression a person is currently experiencing. There are 7 questions each for measuring anxiety and for measuring depression, with 4 possible responses to each question: 0, 1, 2, or 3. Separate scores were calculated for anxiety and depression, both ranging from 0 to 21; a higher score indicates a greater level of anxiety/depression. The recall period was the past 7 days for both the VC and VCE periods. Change from baseline was calculated as the post-baseline value minus the baseline value.

Time frame:
Baseline; Weeks 2, 4, and 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline in the Hospital Anxiety and Depression Scale (HADS) Score at Weeks 2, 4, and 8 of the Double-blind Treatment Period
scores on a scaleVehicle CreamRuxolitinib 1.5% Cream
Change from baseline at Week 2, Anxiety-1.01 ± 0.351-1.68 ± 0.236
Change from baseline at Week 4, Anxiety-1.43 ± 0.389-1.91 ± 0.262
Change from baseline at Week 8, Anxiety-1.26 ± 0.417-2.25 ± 0.271
Change from baseline at Week 2, Depression-0.58 ± 0.305-1.36 ± 0.205
Change from baseline at Week 4, Depression-0.61 ± 0.320-1.56 ± 0.216
Change from baseline at Week 8, Depression-0.33 ± 0.370-1.82 ± 0.239
Statistical analysis
  • Vehicle Cream vs Ruxolitinib 1.5% Cream · Lsm difference: -0.78 · 95% CI -1.50 to -0.05
  • Vehicle Cream vs Ruxolitinib 1.5% Cream · Lsm difference: -0.94 · 95% CI -1.71 to -0.18
  • Vehicle Cream vs Ruxolitinib 1.5% Cream · Lsm difference: -1.49 · 95% CI -2.36 to -0.62
  • Vehicle Cream vs Ruxolitinib 1.5% Cream · Lsm difference: -0.78 · 95% CI -1.50 to -0.05
  • Vehicle Cream vs Ruxolitinib 1.5% Cream · Lsm difference: -0.94 · 95% CI -1.71 to -0.18
  • Vehicle Cream vs Ruxolitinib 1.5% Cream · Lsm difference: -1.49 · 95% CI -2.36 to -0.62
SecondaryChange From Baseline in the HADS Score at Weeks 12, 16, 20, and 24 of the Double-blind Treatment Period

The HADS is a 14-item questionnaire that assesses the levels of anxiety and depression a person is currently experiencing. There are 7 questions each for measuring anxiety and for measuring depression, with 4 possible responses to each question: 0, 1, 2, or 3. Separate scores were calculated for anxiety and depression, both ranging from 0 to 21; a higher score indicates a greater level of anxiety/depression. The recall period was the past 7 days for both the VC and VCE periods. Change from baseline was calculated as the post-baseline value minus the baseline value.

Time frame:
Baseline; Weeks 12, 16, 20, and 24
Reported as:
Mean · scores on a scale
Change From Baseline in the HADS Score at Weeks 12, 16, 20, and 24 of the Double-blind Treatment Period
scores on a scaleVehicle CreamRuxolitinib 1.5% Cream
Baseline, Anxiety6.75 ± 4.6756.62 ± 4.628
Change from baseline at Week 12, Anxiety-2.89 ± 4.536-2.61 ± 4.165
Change from baseline at Week 16, Anxiety-3.14 ± 3.860-2.59 ± 4.681
Change from baseline at Week 20, Anxiety-3.29 ± 3.667-2.64 ± 4.516
Change from baseline at Week 24, Anxiety-3.23 ± 3.898-2.78 ± 4.103
Baseline, Depression4.10 ± 3.5184.53 ± 4.010
Change from baseline at Week 12, Depression-0.89 ± 3.234-1.95 ± 3.570
Change from baseline at Week 16, Depression-0.93 ± 3.362-2.11 ± 4.124
Change from baseline at Week 20, Depression-0.93 ± 3.245-2.08 ± 4.061
Change from baseline at Week 24, Depression-1.85 ± 3.460-2.18 ± 3.623
SecondaryChange From Baseline in the Patient-Reported Outcomes Measurement Information System (PROMIS) Short Form - Sleep-Related Impairment (8a: 7-day Recall) Score at Weeks 2, 4, and 8

The PROMIS Short Form - Sleep-Related Impairment (8a) is an 8-item questionnaire. Each item is rated on a 5-point scale (never, almost never, sometimes, almost always, and always). Individual items are summed to get a total score ranging from 8 to 40; higher scores indicate greater severity of sleep-related impairment. The recall period was 7 days. Change from baseline was calculated as the post-baseline value minus the baseline value.

Time frame:
Baseline; Weeks 2, 4, and 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline in the Patient-Reported Outcomes Measurement Information System (PROMIS) Short Form - Sleep-Related Impairment (8a: 7-day Recall) Score at Weeks 2, 4, and 8
scores on a scaleVehicle CreamRuxolitinib 1.5% Cream
Change from baseline at Week 2-2.18 ± 0.704-4.50 ± 0.474
Change from baseline at Week 4-2.78 ± 0.728-5.86 ± 0.491
Change from baseline at Week 8-2.79 ± 0.778-6.25 ± 0.504
Statistical analysis
  • Vehicle Cream vs Ruxolitinib 1.5% Cream · Lsm difference: -2.32 · 95% CI -3.99 to -0.64
  • Vehicle Cream vs Ruxolitinib 1.5% Cream · Lsm difference: -3.08 · 95% CI -4.81 to -1.35
  • Vehicle Cream vs Ruxolitinib 1.5% Cream · Lsm difference: -3.47 · 95% CI -5.29 to -1.64
SecondaryChange From Baseline in the PROMIS Short Form - Sleep-Related Impairment (8a: 7-day Recall) Score at Weeks 12, 16, 20, and 24

The PROMIS Short Form - Sleep-Related Impairment (8a) is an 8-item questionnaire. Each item is rated on a 5-point scale (never, almost never, sometimes, almost always, and always). Individual items are summed to get a total score ranging from 8 to 40; higher scores indicate greater severity of sleep-related impairment. The recall period was 7 days. Change from baseline was calculated as the post-baseline value minus the baseline value.

Time frame:
Baseline; Weeks 12, 16, 20, and 24
Reported as:
Mean · scores on a scale
Change From Baseline in the PROMIS Short Form - Sleep-Related Impairment (8a: 7-day Recall) Score at Weeks 12, 16, 20, and 24
scores on a scaleVehicle CreamRuxolitinib 1.5% Cream
Baseline21.20 ± 7.62822.03 ± 7.527
Change from baseline at Week 12-4.61 ± 7.777-6.66 ± 8.139
Change from baseline at Week 16-6.93 ± 7.468-8.27 ± 8.283
Change from baseline at Week 20-4.93 ± 5.850-8.48 ± 8.407
Change from baseline at Week 24-7.00 ± 7.649-8.03 ± 8.317
SecondaryChange From Baseline in the PROMIS Short Form - Sleep Disturbance (8b: 7-day Recall) Score at Weeks 2, 4, and 8

The PROMIS Short Form - Sleep-Related Disturbance (8b) is an 8-item questionnaire. Each item is rated on a 5-point scale (never, almost never, sometimes, almost always, and always). Individual items are summed to get a total score ranging from 8 to 40; higher scores indicate greater severity of sleep-related disturbance. The recall period was 7 days. Change from baseline was calculated as the post-baseline value minus the baseline value.

Time frame:
Baseline; Weeks 2, 4, and 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline in the PROMIS Short Form - Sleep Disturbance (8b: 7-day Recall) Score at Weeks 2, 4, and 8
scores on a scaleVehicle CreamRuxolitinib 1.5% Cream
Change from baseline at Week 2-3.22 ± 0.705-5.74 ± 0.474
Change from baseline at Week 4-3.16 ± 0.740-7.06 ± 0.498
Change from baseline at Week 8-3.25 ± 0.847-7.00 ± 0.548
Statistical analysis
  • Vehicle Cream vs Ruxolitinib 1.5% Cream · Lsm difference: -2.51 · 95% CI -4.19 to -0.84
  • Vehicle Cream vs Ruxolitinib 1.5% Cream · Lsm difference: -3.91 · 95% CI -5.67 to -2.15
  • Vehicle Cream vs Ruxolitinib 1.5% Cream · Lsm difference: -3.75 · 95% CI -5.74 to -1.76
SecondaryChange From Baseline in the PROMIS Short Form - Sleep Disturbance (8b: 7-day Recall) Score at Weeks 12, 16, 20, and 24

The PROMIS Short Form - Sleep-Related Disturbance (8b) is an 8-item questionnaire. Each item is rated on a 5-point scale (never, almost never, sometimes, almost always, and always). Individual items are summed to get a total score ranging from 8 to 40; higher scores indicate greater severity of sleep-related disturbance. The recall period was 7 days. Change from baseline was calculated as the post-baseline value minus the baseline value.

Time frame:
Baseline; Weeks 12, 16, 20, and 24
Reported as:
Mean · scores on a scale
Change From Baseline in the PROMIS Short Form - Sleep Disturbance (8b: 7-day Recall) Score at Weeks 12, 16, 20, and 24
scores on a scaleVehicle CreamRuxolitinib 1.5% Cream
Baseline23.65 ± 7.10924.65 ± 7.334
Change from baseline at Week 12-5.17 ± 6.688-7.93 ± 8.643
Change from baseline at Week 16-6.79 ± 6.773-8.75 ± 8.703
Change from baseline at Week 20-5.36 ± 6.122-8.95 ± 8.842
Change from baseline at Week 24-6.31 ± 7.123-8.79 ± 8.634
SecondaryChange From Baseline in the Work Productivity and Activity Impairment Questionairre-Atopic Dermatitis (WPAI-AD) Score at Weeks 8 and 24

The WPAI-AD questionnaire is a validated 6-item instrument that measures the effect of overall health and specific symptoms on productivity at work and regular activities outside of it during the past 7 days. The WPAI outcomes are expressed as impairment percentages (0% to 100% for all outcomes; higher number indicate greater impairment and less productivity \[i.e., worse outcomes\]): Questions: 1 = currently employed; 2 = hours missed due to AD; 3 = hours missed other reasons; 4 = hours actually worked; 5 = degree AD-affected productivity while working; 6 = degree AD-affected regular activities. Scores: multiply scores by 100 to express in percentages: percent work time missed due to AD: Q2 / (Q2 + Q4); percent impairment while working due to AD: Q5 / 10; percent overall work impairment due to AD: Q2 / (Q2 + Q4) + (\[1 - (Q2 / (Q2+Q4)\] × \[Q5/10\]); percent activity impairment due to AD: Q6 / 10. Change from baseline was calculated as the post-baseline value minus the baseline value.

Time frame:
Baseline; Weeks 8 and 24
Reported as:
Mean · scores on a scale
Change From Baseline in the Work Productivity and Activity Impairment Questionairre-Atopic Dermatitis (WPAI-AD) Score at Weeks 8 and 24
scores on a scaleVehicle CreamRuxolitinib 1.5% Cream
Baseline, Percent work time missed due to AD7.55 ± 16.0866.80 ± 16.233
CFB at Week 8, Baseline, Percent work time missed due to AD-0.91 ± 13.613-4.35 ± 16.146
CFB at Week 24, Baseline, Percent work time missed due to AD0.00 ± 0.000-3.21 ± 19.940
Baseline, Percent impairment while working due to AD55.27 ± 21.50446.85 ± 23.855
CFB at Week 8, Percent impairment while working due to AD-18.75 ± 25.996-35.73 ± 26.979
CFB at Week 24, Percent impairment while working due to AD-44.29 ± 28.785-34.67 ± 26.647
Baseline, Percent overall work impairment due to AD57.40 ± 22.99449.20 ± 24.325
CFB at Week 8, Percent overall work impairment due to AD-17.88 ± 26.188-36.66 ± 28.341
CFB at Week 24, Percent overall work impairment due to AD-44.29 ± 28.785-34.79 ± 28.271
Baseline, Percent activity impairment due to AD56.33 ± 24.39955.07 ± 21.836
CFB at Week 8, Percent activity impairment due to AD-20.36 ± 31.216-43.57 ± 25.958
CFB at Week 24, Percent activity impairment due to AD-43.08 ± 40.903-43.92 ± 26.242

Adverse events

Collected over up to approximately 1.5 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vehicle Cream1/81 (1.2%)1/81 (1.2%)12/81 (14.8%)
Ruxolitinib 1.5% BID0/206 (0%)4/206 (1.9%)36/206 (17.5%)
Most frequent serious events
Most frequent serious events
EventVehicle CreamRuxolitinib 1.5% BID
Sudden deathGeneral disorders1/810/206
Abortion spontaneousPregnancy, puerperium and perinatal conditions0/811/206
HypertensionVascular disorders0/811/206
Radius fractureInjury, poisoning and procedural complications0/811/206
Suicide attemptPsychiatric disorders0/811/206
Most frequent other events
Most frequent other events
EventVehicle CreamRuxolitinib 1.5% BID
Upper respiratory tract infectionInfections and infestations4/8124/206
Application site painGeneral disorders5/812/206
NasopharyngitisInfections and infestations4/8112/206

Baseline characteristics

Age, Continuous
Age, Continuous(years)Vehicle CreamRuxolitinib 1.5% CreamTotal
Mean39.7 ± 16.3339.0 ± 16.2939.2 ± 16.27
Sex: Female, Male
Sex: Female, Male(Participants)Vehicle CreamRuxolitinib 1.5% CreamTotal
Female4586131
Male3674110
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Vehicle CreamRuxolitinib 1.5% CreamTotal
White/Caucasian68126194
Black/African-American7714
Asian52025
Native Hawaiian/Pacific Islander011
Not Reported011
Phillipino011
Mix of White and American-Indian101
Missing044
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Vehicle CreamRuxolitinib 1.5% CreamTotal
Hispanic or Latino279
Not Hispanic or Latino78148226
Not Reported011
Unknown101
Missing044
08

Study locations

94 sites
  • Lynn Institute of the Ozarks
    Little Rock, Arkansas 72204, United States
  • First Oc Dermatology
    Fountain Valley, California 92708, United States
  • Center For Dermatology Cosmetic and Laser Surgery
    Fremont, California 94538, United States
  • Medderm Associates, Inc
    San Diego, California 92103, United States
  • Encore Medical Research, Llc Hollywood
    Hollywood, Florida 33021, United States
  • Entrust Clinical Research
    Miami, Florida 33176, United States
  • Lane Dermatology and Dermatologic Surgery
    Columbus, Georgia 31904, United States
  • Marietta Dermatology the Skin Cancer Center Marietta
    Marietta, Georgia 30060, United States
  • Arlington Dermatology
    Rolling Meadows, Illinois 60008, United States
  • Northshore University Healthsystem
    Skokie, Illinois 60077, United States
  • Oakland Hills Dermatology Pc
    Auburn Hills, Michigan 48326, United States
  • Revival Research Institute, Llc Troy
    Troy, Michigan 48084, United States
  • Best Skin Research
    Camp Hill, Pennsylvania 17011, United States
  • International Clinical Research Tennessee Llc
    Murfreesboro, Tennessee 37130, United States
  • Center For Clinical Studies Webster
    Houston, Texas 77004, United States
  • Texas Dermatology Research Center
    Plano, Texas 75025, United States
  • Rainey and Finklea Dermatology
    San Antonio, Texas 78213, United States
  • North Sound Dermatology
    Mill Creek, Washington 98012, United States
  • Premier Specialists Pty Ltd
    Kogarah, New South Wales 02217, Australia
  • Australian Clinical Research Network
    Maroubra, New South Wales 02035, Australia
  • Veracity Clinical Research
    Woolloongabba, Queensland 04102, Australia
  • Clinical Trials Sa
    Campbelltown, South Australia 05074, Australia
  • Skin Health Institute Inc.
    Carlton, Victoria 03053, Australia
  • Paratus Clinical Research, Woden
    Phillip, 02606, Australia
  • Ulb Hospital Erasme
    Brussels, 01070, Belgium
  • Cliniques Universitaires Ucl Saint-Luc
    Brussels, 01200, Belgium
  • Universitair Ziekenhuis Antwerpen (Uza)
    Edegem, 02650, Belgium
  • Universitair Ziekenhuis Gent (Uz Gent)
    Ghent, 09000, Belgium
  • Grand Hopital de Charleroi
    Gilly, 06060, Belgium
  • Dermatologie Handelskaai
    Kortrijk, 08500, Belgium
  • Mhat Dr. Tota Venkova Ad
    Gabrovo, 05300, Bulgaria
  • Medical Center Medconsult Pleven Ood
    Pleven, 05800, Bulgaria
  • Ambulatory For Specialized Medical Help - Skin and Venereal Diseases
    Sofia, 01407, Bulgaria
  • Dcc 'Alexandrovska', Eood
    Sofia, 01431, Bulgaria
  • Medical Center Hera Eood
    Sofia, 01510, Bulgaria
  • Diagnostic Consultative Center Xxviii
    Sofia, 01592, Bulgaria
  • Medical Center Assoc. Prof. Vasilev
    Sofia, 01618, Bulgaria
  • Dermatology Research Institute Inc.
    Calgary, Alberta T2J 7E1, Canada
  • Dr. Chih-Ho Hong Medical Inc.
    Surrey, British Columbia V3R 6A7, Canada
  • Wiseman Dermatology Research Inc
    Winnipeg, Manitoba R3M 3Z4, Canada
  • Dr. Irina Turchin Pc Inc.
    Fredericton, New Brunswick E3B 1G9, Canada
  • Lynderm Research Inc
    Markham, Ontario L3P 1X3, Canada
  • Skin Centre For Dermatology
    Peterborough, Ontario K9J 5K2, Canada
  • Centre de Recherche Dermatologique Du Quebec Metropolitain
    Québec, Quebec G1V 4X7, Canada
  • Skincare Studio Dermatology Centre
    St. John's, A1E 1V4, Canada
  • Ghicl - Hôpital Saint-Vincent de Paul
    Lille, 59020, France
  • Centre Hospitalier Universitaire de Nantes (Chu de Nantes) - Hotel-Dieu
    Nantes, 44093, France
  • Hospices Civils de Lyon Centre Hospitalier Lyon Sud
    Pierre-Bénite, 69495, France
  • Chu de Rouen - Hospital Charles Nicolle
    Rouen, 76000, France
  • University Hospital of Saint Etienne
    Saint-Etienne, 42055, France
  • Universitaetsklinikum Augsburg Sued
    Augsburg, 86179, Germany
  • Fachklinik Bad Bentheim Dermatologie
    Bad Bentheim, 48455, Germany
  • Praxis Fuer Haut- Und Geschlechtskrankheiten Dr. Med. Thomas Wildfeuer Und Partner
    Berlin, 13055, Germany
  • Universitatsklinikum Munster
    Münster, 48149, Germany
  • Dermatologie Potsdam Mvz Gmbh
    Potsdam, 14467, Germany
  • Clinexpert Kft.
    Budapest, 01033, Hungary
  • Obudai Egeszsegugyi Centrum Kft.
    Budapest, 01036, Hungary
  • Semmelweis Egyetem
    Budapest, 01085, Hungary
  • Debreceni Egyetem Klinikai Kozpon Belgyogy Klinika
    Debrecen, 04032, Hungary
  • Szegedi Tudomanyegyetem Aok Szent-Gyorgyi Albert Klinikai Kozpont
    Szeged, 06720, Hungary
  • Fondazione Irccs Ca Granda Ospedale Maggiore
    Milan, 20122, Italy
  • Azienda Ospedaliera Universitaria Federico Ii
    Naples, 80131, Italy
  • Universita Degli Studi Della Campania Luigi Vanvitelli
    Naples, 80131, Italy
  • Fondazione Policlinico Universitario Agostino Gemelli Irccs
    Rome, 00168, Italy
  • Irccs Istituto Clinico Humanitas
    Rozzano, 20089, Italy
  • Bravis Ziekenhuis
    Bergen op Zoom, 4624 VT, Netherlands
  • Amphia Ziekenhuis, Molengracht
    Breda, 04818, Netherlands
  • Universitair Medisch Centrum Groningen
    Groningen, 9713GZ, Netherlands
  • Centrum Badan Klinicznych Pi-House Sp. Z O.O.
    Gdansk, 80-546, Poland
  • Centrum Medyczne Pratia Katowice
    Katowice, 40-081, Poland
  • Centrum Medyczne All-Med
    Krakow, 30-033, Poland
  • Pratia McM Krakow
    Krakow, 30-727, Poland
  • Santa Sp. Z O.O. Santa Familia Ptg Lodz
    Lodz, 90-302, Poland
  • Etg Lublin
    Lublin, 20-412, Poland
  • Solumed Centrum Medyczne
    Poznan, 60-529, Poland
  • Twoja Przychodnia - Szczecinskie Centrum Medyczne
    Szczecin, 71- 500, Poland
  • Centrum Medyczne Evimed
    Warsaw, 02-625, Poland
  • Klinika Ambroziak Dermatologia
    Warsaw, 02-953, Poland
  • Dermmedica Sp. Z O.O.
    Wroclaw, 51-503, Poland
  • Ceim Hospital Universitari Germans Trias I Pujol
    Badalona, 08916, Spain
  • Hospital de La Santa Creu I Sant Pau
    Barcelona, 08041, Spain
  • Hospital Infanta Leonor
    Madrid, 28031, Spain
  • Hospital Universitario de La Paz
    Madrid, 28046, Spain
  • Hospital de Manises
    Manises, 46940, Spain
  • Hospital Marina Baixa
    Villajoyosa, 03570, Spain
  • Universitatsspital Basel
    Basel, CH-4055, Switzerland
  • Inselspital Universitatsklinik Fur Medizinische Onkologie
    Bern, 03010, Switzerland
  • Dermatology & Skin Care Clinic
    Buochs, 06374, Switzerland
  • Universitatsspital Zurich
    Zurich, 08091, Switzerland
  • West Middlesex University Hospital
    Isleworth, TW7 6AF, United Kingdom
  • Guys Hospital
    London, SE1 9RT, United Kingdom
  • Northampton General Hospital
    Northampton, NN1 5BD, United Kingdom
  • University Hospital Plymouth
    Plymouth, PL6 8DH, United Kingdom
  • Walsall Manor Hospital
    Walsall, WS2 9PS, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications

Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.

Data sharing details ↗ · www.incyte.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2024 to primary completion in May 2025, 12 months.

Results were first posted in May 2026, 1 year after primary completion.

Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 12 months is below that.

Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2024
First posted
Feb 2, 2024
StartActual
Apr 26, 2024
Primary completionActual
May 21, 2025
CompletionActual
Oct 17, 2025
Results first posted
May 22, 2026
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Posted results revised
revised Oct 15, 2026
Secondary outcomes
3 edited, 7 time frame changed, 20 description edited, 28 more
What changed in the outcomes
  • EditedVehicle-controlled (VC) Period: Number of Participants With Any Treatment-emergent Adverse Event (TEAE )Time frame: up to Week 12
  • EditedChange From Baseline (Pre-application) in Current Itch NRS Score at 5, 15, 30, 45, and 60 Minutes and 2, 4, and 6 Hours Post-initial Dose on Day 1Time frame: Baseline; Day 1
  • EditedChange From Baseline for Skin Pain NRS Score at Weeks 12, 16, 20, and 24 of the Double-blind Treatment PeriodTime frame: Baseline; Weeks 12, 16, 20, and 24
  • Time frameVehicle-controlled Extension Double-blind (VCE DB) Period: Number of Participants With Any TEAEup to 16 weeks (from Week 8 to Week 24) → up to 20 weeks (from Week 8 to Week 24 plus 30 days)
  • Time frameVCE DB Period: Number of Participants With Any ≥Grade 3 TEAEup to 16 weeks (from Week 8 to Week 24) → up to 20 weeks (from Week 8 to Week 24 plus 30 days)
  • Time frameDouble-blind Treatment Period: Percentage of Participants Achieving EASI50 From Baseline at Weeks 2, 4, 8, 12, 16, 20, and 24Baseline; Weeks 2, 4, 12, 16, 20, and 24 → Baseline; Weeks 2, 4, 8, 12, 16, 20, and 24
  • Time frameDouble-blind Treatment Period: Percentage of Participants With EASI90 From Baseline at Weeks 2, 4, 8, 12, 16, 20, and 24Baseline; Weeks 2, 4, 12, 16, 20, and 24 → Baseline; Weeks 2, 4, 8, 12, 16, 20, and 24
  • Time frameDouble-blind Treatment Period: Percentage of Participants Achieving Both EASI75 and IGA-TS at Weeks 2, 4, 8, 12, 16, 20, and 24Baseline; Weeks 2, 4, 12, 16, 20, and 24 → Baseline; Weeks 2, 4, 8, 12, 16, 20, and 24
  • Time framePercentage of Time Off Study Treatment Due to Lesion Clearance During the VCE DB Periodfrom Week 8 to Week 24 → from Week 8 to Week 12; from Week 12 to Week 16; from Week 16 to Week 20; from Week 20 to Week 24
  • Time framePercentage of Time on Study Treatment During the VCE DB Periodfrom Week 8 to Week 24 → from Week 8 to Week 12; from Week 12 to Week 16; from Week 16 to Week 20; from Week 20 to Week 24
  • DescriptionChange From Baseline for Atopic Dermatitis-affected %BSA at Weeks 12, 16, 20, and 24 of the Double-blind Treatment Period: how it is measured was reworded
  • DescriptionChange From Baseline for Atopic Dermatitis-affected %Body Surface Area (BSA) at Weeks 2, 4, and 8 of the Double-blind Treatment Period: how it is measured was reworded
  • DescriptionChange From Baseline for Itch NRS Score at Days 1 Through 56 (8 Weeks): how it is measured was reworded
  • DescriptionChange From Baseline for Skin Pain NRS Score at Weeks 2, 4, and 8 of the Double-blind Treatment Period: how it is measured was reworded
  • DescriptionChange From Baseline for the EASI Score at Weeks 12, 16, 20, and 24 of the Double-blind Treatment Period: how it is measured was reworded
  • DescriptionChange From Baseline for the EASI Score at Weeks 2, 4, and 8 of the Double-blind Treatment Period: how it is measured was reworded
  • DescriptionChange From Baseline for the SCORAD Score at Weeks 12, 16, 20, and 24 of the Double-blind Treatment Period: how it is measured was reworded
  • DescriptionChange From Baseline for the SCORing Atopic Dermatitis (SCORAD) Score at Weeks 2, 4, and 8 of the Double-blind Treatment Period: how it is measured was reworded
  • DescriptionChange From Baseline in the DLQI Score at Weeks 12, 16, 20, and 24 of the Double-blind Treatment Period: how it is measured was reworded
  • DescriptionChange From Baseline in the DLQI Score at Weeks 2, 4, and 8 of the Double-blind Treatment Period: how it is measured was reworded
  • DescriptionChange From Baseline in the EQ-5D-5L Visual Analog Scale Score at Weeks 12, 16, 20, and 24 of the Double-blind Treatment Period: how it is measured was reworded
  • DescriptionChange From Baseline in the EQ-5D-5L Visual Analog Scale Score at Weeks 2, 4, and 8 of the Double-blind Treatment Period: how it is measured was reworded
  • DescriptionChange From Baseline in the HADS Score at Weeks 12, 16, 20, and 24 of the Double-blind Treatment Period: how it is measured was reworded
  • DescriptionChange From Baseline in the Hospital Anxiety and Depression Scale (HADS) Score at Weeks 2, 4, and 8 of the Double-blind Treatment Period: how it is measured was reworded
  • DescriptionChange From Baseline in the POEM Score at Weeks 12, 16, 20, and 24 of the Double-blind Treatment Period: how it is measured was reworded
  • DescriptionChange From Baseline in the PROMIS Short Form - Sleep Disturbance (8b: 7-day Recall) Score at Weeks 12, 16, 20, and 24: how it is measured was reworded
  • DescriptionChange From Baseline in the PROMIS Short Form - Sleep Disturbance (8b: 7-day Recall) Score at Weeks 2, 4, and 8: how it is measured was reworded
  • DescriptionChange From Baseline in the PROMIS Short Form - Sleep-Related Impairment (8a: 7-day Recall) Score at Weeks 12, 16, 20, and 24: how it is measured was reworded
  • DescriptionChange From Baseline in the Patient-Reported Outcomes Measurement Information System (PROMIS) Short Form - Sleep-Related Impairment (8a: 7-day Recall) Score at Weeks 2, 4, and 8: how it is measured was reworded
  • DescriptionChange From Baseline in the Patient-oriented Eczema Measure (POEM) Score at Weeks 2, 4, and 8 of the Double-blind Treatment Period: how it is measured was reworded
  • …and 28 more, on the record history on ClinicalTrials.gov ↗
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Posted results revised
    Secondary outcomes 3 edited, 7 time frame changed, 20 description edited, 28 more
    What changed in the outcomes
    • EditedVehicle-controlled (VC) Period: Number of Participants With Any Treatment-emergent Adverse Event (TEAE )Time frame: up to Week 12
    • EditedChange From Baseline (Pre-application) in Current Itch NRS Score at 5, 15, 30, 45, and 60 Minutes and 2, 4, and 6 Hours Post-initial Dose on Day 1Time frame: Baseline; Day 1
    • EditedChange From Baseline for Skin Pain NRS Score at Weeks 12, 16, 20, and 24 of the Double-blind Treatment PeriodTime frame: Baseline; Weeks 12, 16, 20, and 24
    • Time frameVehicle-controlled Extension Double-blind (VCE DB) Period: Number of Participants With Any TEAEup to 16 weeks (from Week 8 to Week 24) → up to 20 weeks (from Week 8 to Week 24 plus 30 days)
    • Time frameVCE DB Period: Number of Participants With Any ≥Grade 3 TEAEup to 16 weeks (from Week 8 to Week 24) → up to 20 weeks (from Week 8 to Week 24 plus 30 days)
    • Time frameDouble-blind Treatment Period: Percentage of Participants Achieving EASI50 From Baseline at Weeks 2, 4, 8, 12, 16, 20, and 24Baseline; Weeks 2, 4, 12, 16, 20, and 24 → Baseline; Weeks 2, 4, 8, 12, 16, 20, and 24
    • Time frameDouble-blind Treatment Period: Percentage of Participants With EASI90 From Baseline at Weeks 2, 4, 8, 12, 16, 20, and 24Baseline; Weeks 2, 4, 12, 16, 20, and 24 → Baseline; Weeks 2, 4, 8, 12, 16, 20, and 24
    • Time frameDouble-blind Treatment Period: Percentage of Participants Achieving Both EASI75 and IGA-TS at Weeks 2, 4, 8, 12, 16, 20, and 24Baseline; Weeks 2, 4, 12, 16, 20, and 24 → Baseline; Weeks 2, 4, 8, 12, 16, 20, and 24
    • Time framePercentage of Time Off Study Treatment Due to Lesion Clearance During the VCE DB Periodfrom Week 8 to Week 24 → from Week 8 to Week 12; from Week 12 to Week 16; from Week 16 to Week 20; from Week 20 to Week 24
    • Time framePercentage of Time on Study Treatment During the VCE DB Periodfrom Week 8 to Week 24 → from Week 8 to Week 12; from Week 12 to Week 16; from Week 16 to Week 20; from Week 20 to Week 24
    • DescriptionChange From Baseline for Atopic Dermatitis-affected %BSA at Weeks 12, 16, 20, and 24 of the Double-blind Treatment Period: how it is measured was reworded
    • DescriptionChange From Baseline for Atopic Dermatitis-affected %Body Surface Area (BSA) at Weeks 2, 4, and 8 of the Double-blind Treatment Period: how it is measured was reworded
    • DescriptionChange From Baseline for Itch NRS Score at Days 1 Through 56 (8 Weeks): how it is measured was reworded
    • DescriptionChange From Baseline for Skin Pain NRS Score at Weeks 2, 4, and 8 of the Double-blind Treatment Period: how it is measured was reworded
    • DescriptionChange From Baseline for the EASI Score at Weeks 12, 16, 20, and 24 of the Double-blind Treatment Period: how it is measured was reworded
    • DescriptionChange From Baseline for the EASI Score at Weeks 2, 4, and 8 of the Double-blind Treatment Period: how it is measured was reworded
    • DescriptionChange From Baseline for the SCORAD Score at Weeks 12, 16, 20, and 24 of the Double-blind Treatment Period: how it is measured was reworded
    • DescriptionChange From Baseline for the SCORing Atopic Dermatitis (SCORAD) Score at Weeks 2, 4, and 8 of the Double-blind Treatment Period: how it is measured was reworded
    • DescriptionChange From Baseline in the DLQI Score at Weeks 12, 16, 20, and 24 of the Double-blind Treatment Period: how it is measured was reworded
    • DescriptionChange From Baseline in the DLQI Score at Weeks 2, 4, and 8 of the Double-blind Treatment Period: how it is measured was reworded
    • DescriptionChange From Baseline in the EQ-5D-5L Visual Analog Scale Score at Weeks 12, 16, 20, and 24 of the Double-blind Treatment Period: how it is measured was reworded
    • DescriptionChange From Baseline in the EQ-5D-5L Visual Analog Scale Score at Weeks 2, 4, and 8 of the Double-blind Treatment Period: how it is measured was reworded
    • DescriptionChange From Baseline in the HADS Score at Weeks 12, 16, 20, and 24 of the Double-blind Treatment Period: how it is measured was reworded
    • DescriptionChange From Baseline in the Hospital Anxiety and Depression Scale (HADS) Score at Weeks 2, 4, and 8 of the Double-blind Treatment Period: how it is measured was reworded
    • DescriptionChange From Baseline in the POEM Score at Weeks 12, 16, 20, and 24 of the Double-blind Treatment Period: how it is measured was reworded
    • DescriptionChange From Baseline in the PROMIS Short Form - Sleep Disturbance (8b: 7-day Recall) Score at Weeks 12, 16, 20, and 24: how it is measured was reworded
    • DescriptionChange From Baseline in the PROMIS Short Form - Sleep Disturbance (8b: 7-day Recall) Score at Weeks 2, 4, and 8: how it is measured was reworded
    • DescriptionChange From Baseline in the PROMIS Short Form - Sleep-Related Impairment (8a: 7-day Recall) Score at Weeks 12, 16, 20, and 24: how it is measured was reworded
    • DescriptionChange From Baseline in the Patient-Reported Outcomes Measurement Information System (PROMIS) Short Form - Sleep-Related Impairment (8a: 7-day Recall) Score at Weeks 2, 4, and 8: how it is measured was reworded
    • DescriptionChange From Baseline in the Patient-oriented Eczema Measure (POEM) Score at Weeks 2, 4, and 8 of the Double-blind Treatment Period: how it is measured was reworded
    • …and 28 more, on the record history on ClinicalTrials.gov ↗
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06238817
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Feb 2, 2024
Start date
Apr 26, 2024
Primary completion
May 21, 2025
Completion
Oct 17, 2025
Results posted
May 22, 2026
Last update
Oct 15, 2026

Study contacts

Incyte Medical Monitor
study director · Incyte Corporation

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruxolitinib

Start the discussion